

Transferability of European-derived Alzheimer's disease polygenic risk scores across multiancestry populations

Received: 30 October 2023

Accepted: 29 April 2025

Published online: 18 June 2025



A list of authors and their affiliations appears at the end of the paper

A polygenic score (PGS) for Alzheimer's disease (AD) was derived recently from data on genome-wide significant loci in European ancestry populations. We applied this PGS to populations in 17 European countries and observed a consistent association with the AD risk, age at onset and cerebrospinal fluid levels of AD biomarkers, independently of apolipoprotein E locus (*APOE*). This PGS was also associated with the AD risk in many other populations of diverse ancestries. A cross-ancestry polygenic risk score improved the association with the AD risk in most of the multiancestry populations tested when the *APOE* region was included. Finally, we found that the PGS/polygenic risk score captured AD-specific information because the association weakened as the diagnosis was broadened. In conclusion, a simple PGS captures the AD-specific genetic information that is common to populations of different ancestries, although studies of more diverse populations are still needed to better characterize the genetics of AD.

Over the last 15 years, genome-wide association studies (GWASs) have fostered the development of powerful approaches for characterizing disease processes and the introduction of diagnostic/prognostic tools such as polygenic scores (PGSs)^{1,2}. Given the high estimated heritability (60–80%, in twin studies) of Alzheimer's disease (AD)³, a number of PGSs have been developed; associations with AD risk or related phenotypes have been described for almost all of the scores^{4–10}. However, interstudy comparisons are complicated by marked differences in the populations analyzed, the PGS calculation methods, the summary statistics used and the variants included¹¹. Furthermore, most PGSs have been developed from studies of European ancestry populations, and only a few studies have investigated PGSs performance in populations of different ancestries^{12–15}.

Here, we describe the generation of a PGS (PGS^{ALZ}) that includes the genome-wide significant, independent sentinel single nucleotide polymorphisms (SNPs) at the loci reported by Bellenguez et al.¹⁶, excluding the apolipoprotein E (*APOE*) locus ($n = 83$; see Supplementary Table 1 for the list of variants). We studied the associations between PGS^{ALZ} and AD risk or relevant endophenotypes in populations from 17 European countries and then extended the analysis to populations of diverse

ancestries (from Asia, Africa, Latin America and North America). Finally, as already performed for other complex human diseases^{17–20}, and with a view to improving the predictive performance of PGS^{ALZ} (refs. 2,21), we generated a cross-ancestry polygenic risk score (PRS) by integrating GWAS summary statistics from several populations.

We first evaluated the association between PGS^{ALZ} and AD risk in case–control studies of European countries (see Supplementary Table 2 for population description and adjustments used in each population and Supplementary Figs. 1–3 for PGS^{ALZ} distributions). PGS^{ALZ} was associated significantly with AD risk irrespective of *APOE* adjustment (Extended Data Fig. 1a and Supplementary Fig. 4). PGS^{ALZ} was similarly associated with AD risk in men and in women (Extended Data Fig. 1b and Supplementary Fig. 6). Furthermore, the score was associated with a younger age at onset (Extended Data Fig. 2). It is noteworthy that when the PGSs were adjusted for difference in PGS^{ALZ} distribution between the European populations, the association with AD remained similar (Supplementary Fig. 5).

As we did not identify any potential bias/heterogeneity when comparing PGS^{ALZ} in the European populations, we performed a combined analysis (mega-analysis) of our European datasets to assess

✉ e-mail: dr.aude.nicolas.deydier@gmail.com; jean-charles.lambert@pasteur-lille.fr




Fig. 1 | Associations between the various PGSs and the risk of developing AD as a function of *APOE* status (25,782 AD cases and 35,280 controls). a, The risk of developing AD, by PGS^{ALZ} stratum (0–2%, 2–5%, 10–20%, 20–40%, 60–80%, 80–90%, 90–95%, 95–98% and 98–100%). The 40–60% PGS^{ALZ} stratum was used as the reference. **b**, Risk of developing AD, by PGS^{ALZ} stratum (0–20%, 20–40%, 60–80% and 80–100%) and by *APOE* genotype (by grouping together the ε2ε2/

ε2ε3, ε3ε3, ε2ε4/ε3ε4 and ε4ε4 carriers). The 40–60% PGS^{ALZ} stratum was used as the reference. OR per s.d. was calculated by logistic regression adjusted for age, gender, 14 first PCs and chip center if necessary. The lines indicate the 95% CI of each OR. ε2ε2/ε2ε3 carriers (960 AD cases and 3,604 controls), ε3ε3 (15,623 AD cases and 17,782 controls), ε2ε4/ε3ε4 (8,780 AD cases and 6,242 controls) and ε4ε4 carriers (2,309 AD cases and 479 controls).

the risk of developing AD within various PGS^{ALZ} strata: 0–2%, 2–5%, 10–20%, 20–40%, 60–80%, 80–90%, 90–95%, 95–98% and 98–100%, with the 40–60% PGS^{ALZ} stratum as the reference. We also generated a PGS that included both the sentinel AD GWAS loci and the two SNPs defining the ε2/ε3/ε4 *APOE* alleles. As expected, the risk of developing AD in the most extreme strata was particularly high when *APOE* was included (Fig. 1a). The association with PGS^{ALZ} was also significant in all strata analyzed, irrespective of *APOE* adjustment. In the 0–2% and 98–100% strata, PGS^{ALZ} was associated with a greater than two-fold decrease in AD risk and a greater than threefold increase in AD risk, respectively, compared with the 40–60% stratum (Fig. 1a and Supplementary Table 3).

Since these results suggested that association of PGS^{ALZ} was independent of *APOE*, we leveraged our mega-analysis to determine how PGS^{ALZ} interacted with the *APOE* genotypes. We found a weak interaction between PGS^{ALZ}, the number of *APOE* ε4 alleles and AD risk ($P = 3 \times 10^{-4}$). Next, we stratified the mega-analysis into four *APOE* genotype groups (ε2ε2/ε2ε3, ε3ε3, ε2ε4/ε3ε4 and ε4ε4) and assessed the association between PGS^{ALZ} and AD risk per quintile (0–20%, 20–40%, 60–80% and 80–100%) for each subpopulation (reference, 40–60% stratum). PGS^{ALZ} was associated with AD risk to a similar extent in all strata, although a stronger association might be present among ε4ε4 carriers (Fig. 1b and Supplementary Table 4).

To determine whether PGS^{ALZ} is associated with AD pathophysiological processes, we analyzed GWAS data on CSF levels of Aβ₄₂, tau and p-tau ($n = 13,051$ individuals), as described previously²². PGS^{ALZ} was associated with a decrement in Aβ₄₂ levels and an increment in tau and p-tau levels, whatever the adjustment for *APOE* (Fig. 2a,b and Supplementary Fig. 7). We also checked for a possible association between PGS^{ALZ} and Aβ₄₂ levels, tau and p-tau levels in quintiles (0–20%, 20–40%, 60–80% and 80–100%); again, the 40–60% stratum served as the reference. As expected, PGS^{ALZ} was associated with the lowest and highest levels of p-tau and Aβ₄₂ in the 0–20% strata and, conversely, the highest and lowest levels of p-tau and Aβ₄₂ in the 80–100% stratum (Fig. 2c and Supplementary Table 5).

We then extended the PGS^{ALZ} analyses to other European ancestry populations (United States, Australia), populations from India, East

Asia (China, Japan and Korea), North Africa (Tunisia), sub-Saharan Africa (Central African Republic/the Congo Republic), South America (Argentina, Brazil, Chile and Colombia) and African American, Native American and Latin American ancestry populations from US studies (that is, more than 75% African American or Native American ancestry or self-reporting for Latin American populations; see Extended Data Fig. 3a and Supplementary Table 2 for a description of the population). With the exception of the analyses for Korea and Japan (where 72 and 74 SNPs, respectively, were available), most PGSs were built from 78 to 85 SNPs (including *APOE* variants; see Supplementary Table 1 and Supplementary Figs. 8–10 for PGS^{ALZ} distributions). The strength of the *APOE* ε4-AD association differed from one population to another, as observed previously^{23,24}. The odds ratios (ORs) ranged from 1.36 in sub-Saharan Africa to 5.46 in North Africa (Extended Data Fig. 3b).

As expected, the association between PGS^{ALZ} and AD risk was strongest in European ancestry populations (United States and Australia). PGS^{ALZ} was also significantly associated with AD risk in North African, East Asian, Latin American and African American populations (Fig. 3a and Supplementary Fig. 11). Finally, PGS^{ALZ} was not associated with AD risk in the sub-Saharan African and Indian populations; this might be related to the small sample size and corresponding lack of statistical power. PGS^{ALZ} was associated with a younger age at onset in most of the populations studied, with the notable exception of the Chinese and Korean populations (Extended Data Fig. 4). Of note, the *APOE* ε2/ε3/ε4 alleles influenced age at onset in Chinese and Korean populations (Supplementary Fig. 12).

To refine our analysis of these populations of diverse ancestries, we calculated the association between AD and PGS^{ALZ} quintiles (0–20%, 20–40%, 60–80% and 80–100%; reference, 40–60%) and meta-analyzed them by ancestry (Fig. 3b,c and Supplementary Tables 6 and 7). The Indian, North African and sub-Saharan African populations were excluded because of the small sample size. The strength of the association with PGS^{ALZ} decreased from the European American, East Asian and Latin American populations to the African American population, in that order (Fig. 3b and Supplementary Table 6). PGS^{ALZ} generated from a European ancestry population GWAS performed poorly in African ancestry populations.




Fig. 2 | Association of PGS^{ALZ} with $A\beta_{42}$ and p-tau in cerebrospinal fluid. **a–c.** Association of PGS^{ALZ} with the level of normalized $A\beta_{42}$ (**a**) and p-tau (**b**) in cerebrospinal fluid ($n = 13,004$) across European ancestry populations and according to PGS^{ALZ} strata (0–20%, 20–40%, 60–80% and 80–100%) (**c**); the 40–60% PGS^{ALZ} stratum was used as the reference. β values were calculated by general

linear model and logistic regression adjusted for APOE, age, gender, ten first PCs and chip center if necessary. The horizontal lines in the forest plots indicate the 95% CI of each β value. If heterogeneity P ($HetP$) < 0.05 , a random effect is shown for the meta-analysis results. I^2 ; heterogeneity.

The latter observation was strengthened by analyzing the association between PGS^{ALZ} and AD risk as a function of the African American admixture. The strength of the association decreased as the percentage of African ancestry increased, and ultimately reached a level similar to that observed in our sub-Saharan African population: the association between PGS^{ALZ} and AD risk in populations in whom more than 90% of the members were of African ancestry had an OR of 1.09 (95% confidence interval (CI) 0.98–1.21; $P = 1.4 \times 10^{-1}$, adjusted for APOE). Of note, a similar pattern was observed in the Native American population of the Alzheimer Disease Sequencing Project: the strength of the association decreased as the Native American ancestry percentage increased, from OR = 1.21 (95% CI, 1.12–1.32; $P = 5.3 \times 10^{-6}$) and OR = 1.14 (95% CI, 1.05–1.25; $P = 2.6 \times 10^{-3}$) to OR = 1.12 (95% CI, 1.02–1.24; $P = 1.4 \times 10^{-2}$) in the populations with more than 50%, 75% and 90% of individuals of Native American ancestry, respectively, after adjustment for APOE. A

similar result was found for Chilean and Argentinian populations: the PGS^{ALZ} association weakened as the proportion of individuals with Native American ancestry rose¹⁴.

We next checked that we had fully captured the genetic information in the GWAS-defined loci in the non-European populations. To this end, we developed a PGS (PGS^{ALZ+}) that included other SNPs associated with AD risk in non-European multiethnic populations ($P < 10^{-3}$) at the European GWAS-defined loci (Methods). We used the summary statistics generated by Kunkle et al.²⁵, Lake et al.²⁶ and Shigemizu et al.²⁷, and added 30, 13 and 47 variants to the initial 83 PGS^{ALZ} variants for Latin American, East Asian and African American ancestries, respectively (Supplementary Table 8). We did not detect any increment in (1) the strength of the PGS^{ALZ+} association with the AD risk or (2) PGS^{ALZ+}'s predictive performance, relative to PGS^{ALZ} (Supplementary Table 9).




Fig. 3 | Association of PGS^{ALZ} across multiethnic populations. a, Association of PGS^{ALZ} with the risk of developing AD in multiethnic populations. The European ancestry meta-analysis includes MVP and Australia. The African American ancestry (more than 75% AA ancestry) meta-analysis includes MVP and ADSP. The East Asia meta-analysis includes China, Korea and Japan. The Latin American ancestry (self-reported) meta-analysis includes MVP and ADSP. The South America meta-analysis includes Argentina, Brazil, Chile and Colombia. **b**, The risk of developing AD, according to PGS^{ALZ} (logistic regression adjusted or not for *APOE* or included *APOE* variants) strata (0–20%, 20–40%, 60–80% and 80–100%) in multiethnic populations. The 40–60% PGS^{ALZ} stratum was used as the reference in each population, and results were meta-analyzed. The European

ancestry meta-analysis includes MVP and Australia. The African American ancestry meta-analysis includes MVP and ADSP. The East Asia meta-analysis includes MVP and ADSP. The Latin American ancestry meta-analysis includes MVP and ADSP. The South America meta-analysis includes Argentina, Brazil, Chile and Colombia. N_{cases} , number of cases; N_{controls} , number of controls. OR per s.d. was calculated by logistic regression adjusted for *APOE*, age, sex and specific PCs according to the study (Supplementary Table 2). The lines in the Forest plots indicate the 95% CI of each OR. If $\text{HetP} < 0.05$, a random effect is shown for the meta-analysis results. AA, African American; EUR, European; LA, Latin American.

By initially restricting our analyses to the genome-wide significant loci from European ancestry AD GWAS, we probably excluded genetic information associated with AD risk in both European populations and (especially) non-European multiethnic populations (for which ancestry-specific loci may exist). Furthermore, the effect sizes used to construct PGS^{ALZ} were extracted from European ancestry populations without taking account of population differences. To deal with these various questions, we used the Bayesian polygenic modeling method PRS-CSx to build a cross-ancestry PRS²⁰. The PRS re-estimates variant effect sizes by coupling various summary statistics with external ancestry-matched allele frequencies and local linkage disequilibrium structure, according to the sparseness of the genetic architecture of AD. We used GWAS summary statistics generated from European (36,569 AD cases and 63,137 controls), African American (2,784 AD cases and 5,222 controls), Latin American (1,088 AD cases and 1,152 controls) and East Asian (3,962 AD cases and 4,074 controls) populations^{25–27}. PRSs (all adjusted for the population structure) were generated in multiethnic populations from the Million Veteran Program (MVP; European American, Latin American and African American ancestries), EPIDEMCA (sub-Saharan Africa ancestry) and GARD studies (East Asian ancestry; Supplementary Fig. 13).

We assessed potential increments in the association of PRS with the AD risk and in predictive performance when the summary statistics of the European American, African American, Latin American or East Asian multiethnic populations were applied independently (PRS^{EUR}, PRS^{AA}, PRS^{LA} and PRS^{EA}, respectively) or when the statistics were combined (PRS^{COMB}) at various sparseness values (10^{-8} , 10^{-7} , 10^{-6} ,

10^{-5} , 10^{-4} , 10^{-2} and 1). We initially excluded the *APOE* region, to facilitate the comparison with PGS^{ALZ}. We did not observe any increases in the association with AD risk or in predictive performance in the different multiethnic populations (Fig. 4, Supplementary Fig. 14 and Supplementary Table 10), with the exception of the Latin American MVP population. However, we cannot rule out overfitting as the reason for this improvement. Next, we included the *APOE* region when generating the different PRSs. Whereas no impact on European ancestry populations was observed when comparing PRS^{EUR} and PRS^{COMB}, we detected an increment in both the strength of association with the AD risk and in the predictive performance when comparing PRS^{EUR} and PRS^{COMB} for all other populations. This indicated that a cross-ancestry PRS is more effective than a PRS constructed solely from European summary statistics when the *APOE* region is included, whatever the overall shrinkage value used (Fig. 5, Supplementary Fig. 14 and Supplementary Table 10).

Finally, we leveraged the MVP data to determine how the association between PGS^{ALZ} or PRS^{COMB} (without the *APOE* region) and AD risk changed in multiethnic populations as a function of diagnostic specificity. We looked at how a PGS^{ALZ}/PRS^{COMB} derived from AD case/control studies performed when the diagnosis was broadened to dementia. In all the multiethnic population studied, the association between PGS^{ALZ}/PRS^{COMB} and AD risk weakened as the diagnosis became broader (Fig. 6 and Supplementary Table 11).

Our work produced several important findings. First, the associations between PGS^{ALZ} and AD risk in European populations may be influenced slightly by the *APOE* genotype; this suggests the existence of two independent genetic entities for sporadic AD: one associated




Fig. 4 | Comparison of the association of PGS^{ALZ} or PRS (excluding the *APOE* region) with the AD risk and the corresponding predictive values (adjusted Nagelkerke R^2 and liability R^2). All PGS^{ALZ} and PRS values were adjusted for interpopulation differences in distribution; PRS^{EUR} were generated by using only European ancestry summary statistics; PRS^{COMB} were generated by combining European, African American, Latin American and East Asian ancestry summary

statistics. The sparseness parameter was set to 10^{-8} , 10^{-7} , 10^{-6} , 10^{-5} , 10^{-4} , 10^{-2} or 1. OR per s.d. was calculated by logistic regression adjusted for age, sex and specific PCs according to the study (Supplementary Table 2). MVP EUR (4,561 AD cases and 84,587 controls), MVP LA (375 AD cases and 7,166 controls), MVP AA (713 AD cases and 19,405 controls) and South Korea (1,119 AD cases and 1,172 controls).

with *APOE* $\epsilon 4$ and the other not, as suggested previously²⁸. Second, the simple PGS^{ALZ} (based on the European GWAS-defined loci) seems to be enough to detect an AD genetic risk in most ancestry populations. Our results thus suggest that most of the various ancestry populations are likely to be affected by shared pathophysiological processes that are driven in part by genetic risk factors. Third, in contrast to what has been observed in the genetics of complex traits²⁹ and other multifactorial diseases^{17,30,31}, a cross-ancestry PRS built with a Bayesian polygenic modeling method did not systematically outperform a simple PGS^{ALZ} when the *APOE* locus was excluded. This observation might be due to the small population size of GWAS for the various ancestry populations, which can significantly limit the power of the PRS-CSx approach. However, this might also indicate that a high proportion of AD genetic risk is already accounted for by the European ancestry GWAS-defined loci. Fourth, the *APOE* region appears to contain additional multi-ancestry genetic variability, as suggested previously^{32–35}. Finally, the PGS/PRS associations capture mainly genetic information related to AD because they weakened as the diagnosis was broadened. This observation suggests that the quality of the clinical diagnosis can interfere with the measurement of the association between the PGS/PRS and the AD risk in a given population.

In conclusion, our study of diverse ancestry populations and AD highlights the importance of cross-ancestry analyses for characterizing the genetic complexities of this disease. However, the AD genetics field is still limited by the size of GWASs in these diverse ancestry populations. Furthermore, it is likely that different ancestry populations will differ strongly regarding rare/very rare variants associated with AD risk; this would significantly impact the association of PRSs with AD risk and their predictive abilities³⁶. Better characterization of AD genetics thus requires both GWASs and sequencing studies of more diverse populations.

Online content

Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41588-025-02227-w>.

References

- Osterman, M. D., Kinzy, T. G. & Bailey, J. N. C. Polygenic risk scores. *Curr. Protoc.* **1**, e126 (2021).




Fig. 5 | Association of PRS (including the *APOE* region) with the AD risk and the corresponding predictive values (adjusted Nagelkerke R^2 and liability R^2). All PRS were adjusted for interpopulation differences in distribution; PRS^{EUR} were generated by using only European ancestry summary statistics; PRS^{COMB} were generated by combining European, African American, Latin American and East Asian ancestry summary statistics. The sparseness parameter was set to 10^{-8} , 10^{-7} ,

10^{-6} , 10^{-5} , 10^{-4} , 10^{-3} or 1. OR per s.d. was calculated by logistic regression adjusted for age, sex and specific PCs according to the study (Supplementary Table 2). MVP EUR (4,561 AD cases and 84,587 controls), MVP LA (375 AD cases and 7,166 controls), MVP AA (713 AD cases and 19,405 controls) and South Korea (1,119 AD cases and 1,172 controls).

- Kachuri, L. et al. Principles and methods for transferring polygenic risk scores across global populations. *Nat. Rev. Genet.* **25**, 8–25 (2024).
- Gatz, M. et al. Role of genes and environments for explaining Alzheimer disease. *Arch. Gen. Psychiatry* **63**, 168–174 (2006).
- Baker, E. & Escott-Price, V. Polygenic risk scores in Alzheimer's disease: current applications and future directions. *Front. Digit. Health* **2**, 14 (2020).
- Desikan, R. S. et al. Genetic assessment of age-associated Alzheimer disease risk: development and validation of a polygenic hazard score. *PLoS Med.* **14**, e1002258 (2017).
- Sabuncu, M. R. et al. The association between a polygenic Alzheimer score and cortical thickness in clinically normal subjects. *Cereb. Cortex* **22**, 2653–2661 (2012).
- Mormino, E. C. et al. Polygenic risk of Alzheimer disease is associated with early- and late-life processes. *Neurology* **87**, 481–488 (2016).
- Xicota, L. et al. Association of APOE-independent Alzheimer disease polygenic risk score with brain amyloid deposition in asymptomatic older adults. *Neurology* **99**, e462–e475 (2022).
- Slegers, K. et al. A 22-single nucleotide polymorphism Alzheimer's disease risk score correlates with family history, onset age, and cerebrospinal fluid A β 42. *Alzheimers Dement.* **11**, 1452–1460 (2015).
- Hong, S. et al. Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD multimodal biomarker discovery dataset. *Transl. Psychiatry* **10**, 403 (2020).
- Clark, K., Leung, Y. Y., Lee, W.-P., Voight, B. & Wang, L.-S. Polygenic risk scores in Alzheimer's disease genetics: methodology, applications, inclusion, and diversity. *J. Alzheimers Dis.* **89**, 14 (2022).
- Sariya, S. et al. Polygenic risk score for Alzheimer's disease in Caribbean Hispanics. *Ann. Neurol.* **90**, 366–376 (2021).
- Jung, S.-H. et al. Transferability of Alzheimer disease polygenic risk score across populations and its association with Alzheimer disease-related phenotypes. *JAMA Netw. Open* **5**, e2247162 (2022).
- Dalmasso, M. C. et al. The first genome-wide association study in the Argentinian and Chilean populations identifies shared genetics with Europeans in Alzheimer's disease. *Alzheimers Dement.* **20**, 1298–1308 (2024).




Fig. 6 | Association of PGS^{ALZ} or PRS^{COMB} (excluding the *APOE* region) with AD, AD and related dementia (ADRD) and dementia in MVP, and the corresponding predictive values (adjusted Nagelkerke R^2 and liability R^2). PGS^{ALZ} and PRS^{COMB} were adjusted for interpopulation differences in distribution; PRS^{COMB} were generated by combining European, African American and Latin American and East Asian ancestry summary statistics. The sparseness parameter

was set to 10^{-8} and 10^{-6} . OR per s.d. was calculated by logistic regression adjusted for age, sex and specific PCs according to the study (Supplementary Table 2). MVP EUR (4,561 AD; 17,519 ADRD; 26,473 dementia cases and 84,587 controls), MVP LA (375 AD; 1,527 ADRD; 1,981 dementia cases and 7,166 controls), MVP AA (713 AD; 4,016 ADRD; 4,702 dementia cases and 19,405 controls).

15. Kikuchi, M. et al. Polygenic effects on the risk of Alzheimer's disease in the Japanese population. *Alzheimers Res. Ther.* **16**, 45 (2024).
16. Bellenguez, C. et al. New insights into the genetic etiology of Alzheimer's disease and related dementias. *Nat. Genet.* **54**, 412–436 (2022).
17. Koyama, S. et al. Population-specific and trans-ancestry genome-wide analyses identify distinct and shared genetic risk loci for coronary artery disease. *Nat. Genet.* **52**, 1169–1177 (2020).
18. Lennon, N. J. et al. Selection, optimization and validation of ten chronic disease polygenic risk scores for clinical implementation in diverse US populations. *Nat. Med.* **30**, 480–487 (2024).
19. Keaton, J. M. et al. Genome-wide analysis in over 1 million individuals of European ancestry yields improved polygenic risk scores for blood pressure traits. *Nat. Genet.* **56**, 778–791 (2024).
20. Ge, T. et al. Development and validation of a trans-ancestry polygenic risk score for type 2 diabetes in diverse populations. *Genome Med.* **14**, 70 (2022).
21. Xiang, R. et al. Recent advances in polygenic scores: translation, equitability, methods and FAIR tools. *Genome Med.* **16**, 33 (2024).
22. Jansen, I. E. et al. Genome-wide meta-analysis for Alzheimer's disease cerebrospinal fluid biomarkers. *Acta Neuropathol.* **144**, 821–842 (2022).
23. Logue, M. W., Dasgupta, S. & Farrer, L. A. Genetics of Alzheimer's disease in the African American population. *J Clin. Med.* **12**, 5189 (2023).
24. Miyashita, A., Kikuchi, M., Hara, N. & Ikeuchi, T. Genetics of Alzheimer's disease: an East Asian perspective. *J. Hum. Genet.* **68**, 115–124 (2023).
25. Kunkle, B. W. et al. Novel Alzheimer disease risk loci and pathways in African American individuals using the African Genome Resources Panel: a meta-analysis. *JAMA Neurol.* **78**, 102–113 (2021).
26. Lake, J. et al. Multi-ancestry meta-analysis and fine-mapping in Alzheimer's disease. *Mol. Psychiatry* **28**, 3121–3132 (2023).
27. Shigemizu, D. et al. Ethnic and trans-ethnic genome-wide association studies identify new loci influencing Japanese Alzheimer's disease risk. *Transl. Psychiatry* **11**, 151 (2021).

28. Frisoni, G. B. et al. The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. *Nat. Rev. Neurosci.* **23**, 53–66 (2022).
29. Wang, Y. et al. Polygenic prediction across populations is influenced by ancestry, genetic architecture, and methodology. *Cell Genomics* **3**, 100408 (2023).
30. Smith, J. L. et al. Multi-ancestry polygenic risk score for coronary heart disease based on an ancestrally diverse genome-wide association study and population-specific optimization. *Circ. Genom. Precis. Med.* **17**, e004272 (2024).
31. Khan, A. et al. Genome-wide polygenic score to predict chronic kidney disease across ancestries. *Nat. Med.* **28**, 1412–1420 (2022).
32. Naslavsky, M. S. et al. Global and local ancestry modulate APOE association with Alzheimer's neuropathology and cognitive outcomes in an admixed sample. *Mol. Psychiatry* **27**, 4800–4808 (2022).
33. Rajabli, F. et al. Ancestral origin of ApoE ϵ 4 Alzheimer disease risk in Puerto Rican and African American populations. *PLoS Genet.* **14**, e1007791 (2018).
34. Bussies, P. L. et al. Use of local genetic ancestry to assess TOMM40-523' and risk for Alzheimer disease. *Neurol. Genet.* **6**, e404 (2020).
35. Rajabli, F. et al. A locus at 19q13.31 significantly reduces the ApoE ϵ 4 risk for Alzheimer's disease in African Ancestry. *PLoS Genet.* **18**, e1009977 (2022).
36. Nagao, Y. Contribution of rare variants to heritability of a disease is much greater than conventionally estimated: modification of allele distribution model. *J. Hum. Genet.* **69**, 663–668 (2024).

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

© The Author(s) 2025

Aude Nicolas^{1,2,342}✉, Richard Sherva^{3,4,342}, Benjamin Grenier-Boley^{1,342}, Yoontae Kim^{5,342}, Masataka Kikuchi⁶, Jigyasha Timsina^{7,8}, Itziar de Rojas^{9,10}, María Carolina Dalmasso^{11,12}, Xiaopu Zhou^{13,14,15}, Yann Le Guen^{16,17}, Carlos E. Arboleda-Bustos¹⁸, Maria Aparecida Camargos Bicalho^{19,20,21}, Maëleenn Guerchet²², Sven van der Lee^{23,24}, Monica Goss²⁵, Atahualpa Castillo²⁶, Céline Bellenguez¹, Fahri Küçükali^{27,28}, Claudia L. Satizabal^{25,29,30}, Bernard Fongang^{25,31,32}, Qiong Yang^{29,30}, Oliver Peters^{33,34}, Anja Schneider^{35,36}, Martin Dichgans^{37,38,39}, Dan Rujescu⁴⁰, Norbert Scherbaum⁴¹, Jürgen Deckert⁴², Steffi Riedel-Heller⁴³, Lucrezia Hausner⁴⁴, Laura Molina-Porcel^{45,46}, Emrah Düzel^{47,48}, Timo Grimmer⁴⁹, Jens Wiltfang^{50,51,52}, Stefanie Heilmann-Heimbach⁵³, Susanne Moebus⁵⁴, Thomas Teges⁵⁵, Nikolaos Scarmeas^{56,57}, Oriol Dols-Icardo^{10,58}, Fermin Moreno^{10,59,60}, Jordi Pérez-Tur^{10,61}, María J. Bullido^{10,62,63,64}, Pau Pastor^{65,66}, Raquel Sánchez-Valle⁶⁷, Victoria Álvarez^{68,69}, Han Cao¹³, Nancy Y. Ip^{13,14,15}, Amy K. Y. Fu^{13,14,15}, Fanny C. F. Ip^{14,15}, Natividad Olivar⁷⁰, Carolina Muchnik⁷⁰, Carolina Cuesta⁷¹, Lorenzo Campanelli⁷², Patricia Solis⁷³, Daniel Gustavo Politis⁷¹, Silvia Kochen⁷³, Luis Ignacio Brusco⁷⁰, Mercè Boada^{9,10}, Pablo García-González⁹, Raquel Puerta⁹, Pablo Mir^{10,74}, Luis M. Real^{10,75,76}, Gerard Piñol-Ripoll^{77,78}, Jose María García-Alberca^{10,79}, Jose Luis Royo⁸⁰, Eloy Rodríguez-Rodríguez^{10,81}, Hilkka Soininen⁸², Sami Heikkinen⁸³, Alexandre de Mendonça⁸⁴, Shima Mehrabian⁸⁵, Latchezar Traykov⁸⁶, Jakub Hort^{87,88}, Martin Vyhnaek^{87,88}, Katrine Laura Rasmussen^{89,90}, Jesper Qvist Thomassen⁸⁹, Yolande A. L. Pijnenburg²³, Henne Holstege^{23,91}, John C. van Swieten⁹², Harro Seelaar⁹², Jurgen A. H. R. Claassen^{93,94}, Willemijn J. Jansen⁹⁵, Inez Ramakers⁹⁵, Frans Verhey⁹⁵, Aad van der Lugt⁹⁶, Philip Scheltens²³, Jenny Ortega-Rojas¹⁸, Ana Gabriela Concha Mera¹⁸, Maria F. Mahecha¹⁸, Rodrigo Pardo¹⁸, Gonzalo Arboleda¹⁸, Shahram Bahrami^{97,98}, Vera Fominykh^{97,98}, Geir Selbæk^{99,100,101}, Caroline Graff¹⁰², Goran Papenberg¹⁰³, Vilmantas Giedraitis¹⁰⁴, Anne Boland¹⁰⁵, Jean-François Deleuze¹⁰⁵, Luiz Armando de Marco^{20,106}, Edgar Nunes de Moraes^{19,21}, Bernardo de Mattos Viana^{20,107,108}, Marco Túlio Gualberto Cintra^{19,21}, Teresa Juarez-Cedillo¹⁰⁹, Anthony J. Griswold¹¹⁰, Tatiana Forund¹¹¹, Jonathan Haines¹¹², Lindsay Farrer^{4,113,114,115,116}, Anita DeStefano¹¹³, Ellen Wijsman^{117,118,119}, Richard Mayeux^{120,121}, Margaret Pericak-Vance^{110,122}, Brian Kunkle¹¹⁰, Alison Goate¹²³, Gerard D. Schellenberg¹²⁴, Badri Vardarajan^{120,121,125}, Li-San Wang¹²⁴, Yuk Yee Leung¹²⁴, Clifton L. Dalgard^{126,127}, Gael Nicolas¹²⁸, David Wallon¹²⁸, Carole Dufouil^{129,130}, Florence Pasquier¹³¹, Olivier Hanon¹³², Stéphanie Debette^{133,134}, Edna Grünblatt^{135,136,137}, Julius Popp^{138,139,140}, Bárbara Angel^{141,142}, Sergio Gloger^{143,144}, Maria Victoria Chacon¹⁴³, Rafael Aranguiz^{143,145,146}, Paulina Orellana^{147,148}, Andrea Slachevsky^{147,149}, Christian Gonzalez-Billault^{141,147}, Cecilia Albala^{141,142}, Patricio Fuentes^{150,151}, Perminder Sachdev¹⁵², Karen A. Mather¹⁵², Richard L. Hauger^{153,154}, Victoria Merritt^{155,156,157}, Matthew Panizzon^{154,156,157}, Rui Zhang³, J. Michael Gaziano^{158,159}, Roberta Ghidoni¹⁶⁰, Daniela Galimberti^{161,162}, Beatrice Arosio¹⁶³, Patrizia Mecocci^{164,165}, Vincenzo Solfrizzi¹⁶⁶, Lucilla Parnetti¹⁶⁷, Alessio Squassina¹⁶⁸, Lucio Tremolizzo¹⁶⁹, Barbara Borroni^{170,171}, Benedetta Nacmias^{172,173}, Paolo Caffarra¹⁷⁴, Davide Seripa¹⁷⁵, Innocenzo Rainero¹⁷⁶, Antonio Daniele^{177,178}, Fabrizio Piras¹⁷⁹,

EADB*, Hampton L. Leonard^{180,181}, Jenifer S. Yokoyama^{181,182,183,184}, Mike A. Nalls^{180,181,185}, Akinori Miyashita¹⁸⁶, Norikazu Hara¹⁸⁶, Kouichi Ozaki¹⁸⁷, Shumpei Niida¹⁸⁷, Julie Williams^{186,188}, Carlo Masullo¹⁸⁹, Philippe Amouyel¹, Pierre-Marie Preux²², Pascal Mbelesso^{22,190}, Bébène Bandzouzi¹⁹¹, Andy Saykin^{111,192}, Frank Jessen^{35,193,194}, Patrick G. Kehoe¹⁹⁵, Cornelia Van Duijn^{196,197}, Nesrine Ben Salem¹⁹⁸, Ruth Frikke-Schmidt^{89,90}, Lotfi Cherni^{198,199}, Michael D. Greicius¹⁶, Magda Tsolaki^{10,200}, Pascual Sánchez-Juan^{10,200}, Marco Aurélio Romano Silva^{20,107}, Tenielle Porter^{201,202,203}, Simon M. Laws^{201,202,203}, Kristel Slegers^{27,28}, Martin Ingelsson^{204,205,206}, Jean-François Dartigues²⁰⁷, Sudha Seshadri^{25,29,30}, Giacomina Rossi²⁰⁸, Laura Morelli⁷², Mikko Hiltunen⁸³, Rebecca Sims²⁶, Wiesje van der Flier²³, Ole A. Andreassen^{97,98}, Humberto Arboleda¹⁸, Carlos Cruchaga^{7,8}, Valentina Escott-Price^{188,209}, Agustín Ruiz^{9,10,210}, Kun Ho Lee^{5,211,212}, Takeshi Ikeuchi¹⁸⁶, Alfredo Ramirez^{210,213,214,215,216}, Jungsoo Gim^{5,211,212,343}, Mark Logue^{3,113,217,218,343} & Jean-Charles Lambert^{1,343} ✉

¹U1167-RID-AGE facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, Université Lille, Inserm, CHU Lille, Institut Pasteur de Lille, Lille, France. ²Institut du Cerveau - Paris Brain Institute - ICM, Sorbonne Université, CNRS, APHP Hôpital de La Pitié Salpêtrière, Inserm, Paris, France. ³Behavioral Sciences Division, National Center for PTSD, VA Boston Healthcare System, Boston, MA, USA. ⁴Department of Medicine (Biomedical Genetics), Boston University, Boston, MA, USA. ⁵BK FOUR Department of Integrative Biological Sciences, Chosun University, Gwangju, Republic of Korea. ⁶Graduate School of Frontier Science, University of Tokyo, Tokyo, Japan. ⁷Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA. ⁸NeuroGenomics and Informatics Center, Washington University School of Medicine, St. Louis, MO, USA. ⁹ACE Alzheimer Center Barcelona, Universitat Internacional de Catalunya, Barcelona, Spain. ¹⁰CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain. ¹¹Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital Cologne, Division of Neurogenetics and Molecular Psychiatry, University of Cologne, Cologne, Germany. ¹²Studies in Neuroscience and Complex Systems Unit (ENyS) CONICET-HEC-UNAJ, Santiago, Chile. ¹³Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Kowloon, China. ¹⁴Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China. ¹⁵Guangdong Provincial Key Laboratory of Brain Science, Disease and Drug Development, HKUST Shenzhen Research Institute Shenzhen-Hong Kong Institute of Brain Science, Shenzhen, China. ¹⁶Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA. ¹⁷Institut du Cerveau, Paris Brain Institute - ICM, Paris, France. ¹⁸Neuroscience and Cell Death Research Groups, Medical School and Genetic Institute, Universidad Nacional de Colombia, Bogotá, Colombia. ¹⁹Department of Clinical Medicine, Federal University of Minas Gerais (UFMG) Belo Horizonte, Minas Geraes, Brazil. ²⁰National Institute of Science and Technology (INCT) Neurotec R, Federal University of Minas Gerais Belo Horizonte, Minas Geraes, Brazil. ²¹Geriatrics Service of the University Hospital, Federal University of Minas Gerais Belo Horizonte, Minas Geraes, Brazil. ²²EpiMaCT - Epidemiology of chronic diseases in tropical zone, Inserm U1094, IRD UMR270, Université Limoges, CHU Limoges, Institute of Epidemiology and Tropical Neurology, OmegaHealth, Limoges, France. ²³Department of Neurology, Alzheimer Center Amsterdam, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. ²⁴Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, Vrije University, Amsterdam, the Netherlands. ²⁵Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, San Antonio, TX, USA. ²⁶Division of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Cardiff, UK. ²⁷Complex Genetics of Alzheimer's Disease Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium. ²⁸Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium. ²⁹Boston University and the NHLBI's Framingham Heart Study, Boston, MA, USA. ³⁰Department of Neurology, Boston University School of Medicine, Boston, MA, USA. ³¹Department of Biochemistry and Structural Biology, University of Texas Health Science Center, San Antonio, TX, USA. ³²Department of Population Health Sciences, University of Texas Health Science Center, San Antonio, TX, USA. ³³German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany. ³⁴Institute of Psychiatry and Psychotherapy, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany. ³⁵German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany. ³⁶Department for Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany. ³⁷Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany. ³⁸German Center for Neurodegenerative Diseases (DZNE), Munich, Germany. ³⁹Munich Cluster for Systems Neurology (SyNergy), Munich, Germany. ⁴⁰Department of Psychiatry and Comprehensive Center of Neuroscience and Mental Health, Medical University of Vienna, Vienna, Austria. ⁴¹Department of Psychiatry and Psychotherapy, LVR-University Hospital Essen, Medical Faculty of the University of Duisburg-Essen, Essen, Germany. ⁴²Department of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Würzburg, Würzburg, Germany. ⁴³Institute of Social Medicine, Occupational Health and Public Health, University of Leipzig, Leipzig, Germany. ⁴⁴Department of Geriatric Psychiatry, Central Institute for Mental Health Mannheim, Faculty Mannheim, University of Heidelberg, Heidelberg, Germany. ⁴⁵Neurological Tissue Bank - Biobanc, Hospital Clinic, FRCB, IDIBAPS, Barcelona, Spain. ⁴⁶Neurology Department, Alzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clinic, Barcelona, Spain. ⁴⁷German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany. ⁴⁸Institute of Cognitive Neurology and Dementia Research (IKND), Otto-von-Guericke University, Magdeburg, Germany. ⁴⁹Department of Psychiatry and Psychotherapy, Center for Cognitive Disorders, Technical University of Munich, School of Medicine, Munich, Germany. ⁵⁰Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, Goettingen, Germany. ⁵¹German Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany. ⁵²Medical Science Department, iBiMED, Aveiro, Portugal. ⁵³Institute of Human Genetics, University of Bonn, School of Medicine and University Hospital Bonn, Bonn, Germany. ⁵⁴Institute for Urban Public Health, University Hospital Essen, University Duisburg-Essen, Essen, Germany. ⁵⁵First Department of Neurology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece. ⁵⁶First Department of Neurology, Aiginion Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece. ⁵⁷Department of Neurology, Columbia University, New York, NY, USA. ⁵⁸Genetics of Neurodegenerative Diseases Unit IIB Sant Pau, Barcelona, Spain. ⁵⁹Department of Neurology, Hospital Universitario Donostia, San Sebastian, Spain. ⁶⁰Neurosciences Area, Instituto Biogipuzkoa, San Sebastian, Spain. ⁶¹Unitat de Genètica Molecular, Institut de Biomedicina de València-CSIC, Valencia, Spain. ⁶²Centro de Biología Molecular Severo Ochoa (UAM-CSIC), Madrid, Spain. ⁶³Instituto de Investigación Sanitaria 'Hospital la Paz' (IdIPaz), Madrid, Spain. ⁶⁴Universidad Autónoma de Madrid, Madrid, Spain. ⁶⁵Department of Neurology, Unit of Neurodegenerative Diseases, University Hospital Germans Trias i Pujol, Badalona, Spain. ⁶⁶The Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain. ⁶⁷Alzheimer's Disease and Other Cognitive Disorders Unit, Service of Neurology, Hospital Clínic of Barcelona. Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain. ⁶⁸Laboratorio de Genética, Hospital Universitario Central de Asturias, Oviedo, Spain. ⁶⁹Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain. ⁷⁰Center of Neuropsychiatry and

Behavior Neurology, School of Medicine, University of Buenos Aires, Buenos Aires, Argentina. ⁷¹Hospital Interzonal General de Agudos-Eva Perón, Buenos Aires, Argentina. ⁷²Laboratory of Brain Aging and Neurodegeneration. Fundación Instituto Leloir-IBBA, Buenos Aires, Argentina. ⁷³Studies in Neuroscience and Complex Systems Unit-CONICET-HEC-UNAJ, Buenos Aires, Argentina. ⁷⁴Unidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Instituto de Biomedicina de Sevilla (IBIS) Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain. ⁷⁵Instituto de Biomedicina de Sevilla, IBIS/Hospital Universitario Virgen de Valme, Sevilla, Spain. ⁷⁶Departamento de Bioquímica Médica, Biología Molecular e Inmunología, Facultad de Medicina, Universidad de Sevilla, Sevilla, Spain. ⁷⁷Unitat Trastorns Cognitius, Hospital Universitari Santa Maria de Lleida, Lleida, Spain. ⁷⁸Institut de Recerca Biomedica de Lleida (IRBLleida), Lleida, Spain. ⁷⁹Alzheimer Research Center and Memory Clinic, Andalusian Institute for Neuroscience, Málaga, Spain. ⁸⁰Departamento de Especialidades Quirúrgicas, Bioquímica e Inmunología, Facultad de Medicina, Universidad de Málaga, Málaga, Spain. ⁸¹Neurology Service, Marqués de Valdecilla University Hospital (University of Cantabria and IDIVAL), Santander, Spain. ⁸²Institute of Clinical Medicine—Neurology, University of Eastern Finland, Kuopio, Finland. ⁸³Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland. ⁸⁴Faculty of Medicine, University of Lisbon, Lisbon, Portugal. ⁸⁵Clinic of Neurology, UH Alexandrovska, Medical University, Sofia, Bulgaria. ⁸⁶Department of Neurology, UH Alexandrovska, Medical University, Sofia, Bulgaria. ⁸⁷Department of Neurology, Memory Clinic, Charles University, Second Faculty of Medicine and Motol University Hospital, Brno, Czech Republic. ⁸⁸International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic. ⁸⁹Department of Clinical Biochemistry, Copenhagen University Hospital—Rigshospitalet, Copenhagen, Denmark. ⁹⁰Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. ⁹¹Department of Clinical Genetics, VU University Medical Centre, Amsterdam, the Netherlands. ⁹²Alzheimer Center, Department of Neurology, Erasmus MR, Rotterdam, the Netherlands. ⁹³Department of Geriatrics, Radboud University Medical Center, Research Institute for Medical Innovation, Rotterdam, the Netherlands. ⁹⁴Department of Cardiovascular Sciences, University of Leicester, Leicester, UK. ⁹⁵Department of Psychiatry and Neuropsychology, Maastricht University, Alzheimer Center Limburg, Maastricht, the Netherlands. ⁹⁶Department of Radiology, ErasmusMC, Rotterdam, the Netherlands. ⁹⁷Division of Mental Health and Addiction, NORMENT Centre, Oslo University Hospital, Oslo, Norway. ⁹⁸Institute of Clinical Medicine, University of Oslo, Oslo, Norway. ⁹⁹Norwegian Centre for Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway. ¹⁰⁰Faculty of Medicine, University of Oslo, Oslo, Norway. ¹⁰¹Department of Geriatric Medicine, Oslo University Hospital, Oslo, Norway. ¹⁰²Unit for Hereditary Dementias, Theme Aging, Karolinska University Hospital—Solna, Stockholm, Sweden. ¹⁰³Department of Neurobiology, Care Sciences and Society, Aging Research Center, Karolinska Institutet and Stockholm University, Stockholm, Sweden. ¹⁰⁴Department of Public Health and Carins Sciences/Geriatrics, Uppsala University, Uppsala, Sweden. ¹⁰⁵Université Paris-Saclay, CEA, Centre National de Recherche en Génomique Humaine (CNRGH), Evry, France. ¹⁰⁶Department of Surgery, Federal University of Minas Gerais (UFMG) Belo Horizonte, Minas Gerais, Brazil. ¹⁰⁷Department of Psychiatry, Federal University of Minas Gerais (UFMG) Belo Horizonte, Minas Gerais, Brazil. ¹⁰⁸Psychiatry Service of the University Hospital, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. ¹⁰⁹Unidad de Investigación Epidemiológica y en Servicios de Salud, Área Envejecimiento, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico. ¹¹⁰The John P. Hussman Institute for Human Genomics, University of Miami, Miami, FL, USA. ¹¹¹Department of Medical and Molecular Genetics, Indiana University, Indianapolis, IN, USA. ¹¹²Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH, USA. ¹¹³Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA. ¹¹⁴Department of Epidemiology, Boston University, Boston, MA, USA. ¹¹⁵Department of Neurology, Boston University, Boston, MA, USA. ¹¹⁶Department of Ophthalmology, Boston University, Boston, MA, USA. ¹¹⁷Department of Medicine (Medical Genetics), University of Washington, Seattle, WA, USA. ¹¹⁸Department of Biostatistics, University of Washington, Seattle, WA, USA. ¹¹⁹Department of Genome Sciences, University of Washington, Seattle, WA, USA. ¹²⁰Department of Neurology, Taub Institute on Alzheimer's Disease and the Aging Brain, Columbia University, New York, NY, USA. ¹²¹Gertrude H. Sergievsky Center, Columbia University, New York, NY, USA. ¹²²Dr. John T. Macdonald Foundation Department of Human Genetics, University of Miami, Miami, FL, USA. ¹²³Department of Neuroscience, Mount Sinai School of Medicine, New York, NY, USA. ¹²⁴Department of Pathology and Laboratory Medicine, Penn Neurodegeneration Genomics Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. ¹²⁵Department of Neurology, Columbia University, New York, NY, USA. ¹²⁶Department of Anatomy, Physiology and Genetics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA. ¹²⁷Center for Military Precision Health, The American Genome Center, Uniformed Services University of the Health Sciences, Bethesda, MD, USA. ¹²⁸Department of Genetics and CNR-MAJ, Université Rouen Normandie, Normandie Université, Inserm U1245 and CHU Rouen, Rouen, France. ¹²⁹Bordeaux Population Health Research Center, Inserm, UMR 1219, Université Bordeaux, ISPED, CIC 1401-EC, Université Bordeaux, Bordeaux, France. ¹³⁰CHU de Bordeaux, Pole Santé Publique, Bordeaux, France. ¹³¹CHU Clinical and Research Memory Research Centre (CMRR) of Distal Lille France, Université Lille Inserm 1171, Paris, France. ¹³²Hôpital Broca, Université de Paris, EA 4468, AHP, Paris, France. ¹³³Bordeaux Population Health Research Center, University Bordeaux, Inserm, Bordeaux, France. ¹³⁴Department of Neurology, Bordeaux University Hospital, Bordeaux, France. ¹³⁵Department of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, University of Zurich, Zurich, Switzerland. ¹³⁶Neuroscience Center Zurich, University of Zurich and ETH Zurich, Zurich, Switzerland. ¹³⁷Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland. ¹³⁸Department of Psychiatry, Old Age Psychiatry, Lausanne University Hospital, Lausanne, Switzerland. ¹³⁹Department of Geriatric Psychiatry, University Hospital of Psychiatry Zürich, Zurich, Switzerland. ¹⁴⁰Institute for Regenerative Medicine, University of Zürich, Zurich, Switzerland. ¹⁴¹Public Health Nutrition Unit, Institute of Nutrition and Food Technology, University of Chile, Santiago de Chile, Chile. ¹⁴²Interuniversity Center for Healthy Aging RED21993, Santiago de Chile, Chile. ¹⁴³Biomedica Research Group, Centro de Estudios Clínicos, Santiago, Chile. ¹⁴⁴Departamento de Psiquiatría y Salud Mental, Campus Oriente, Facultad de Medicina Universidad de Chile, Santiago, Chile. ¹⁴⁵Instituto Nacional de Geriátrica, Santiago, Chile. ¹⁴⁶Department of Neurology and Psychiatry, Clínica Alemana, Santiago, Chile. ¹⁴⁷Geroscience Center for Brain Health and Metabolism, Santiago, Chile. ¹⁴⁸Latin American Institute for Brain Health (BrainLat), Universidad Adolfo Ibáñez, Santiago, Chile. ¹⁴⁹Memory and Neuropsychiatric Center (CMYN) Neurology Department, Hospital del Salvador y Facultad de Medicina, Universidad de Chile, Santiago, Chile. ¹⁵⁰Geriatrics Section Clinical Hospital University of Chile, Santiago de Chile, Chile. ¹⁵¹Neurology Service Hospital del Salvador, Santiago, Chile. ¹⁵²Centre for Healthy Brain Ageing School of Psychiatry, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia. ¹⁵³Center of Excellence for Stress and Mental Health (CESAMH), VA San Diego Healthcare System, San Diego, CA, USA. ¹⁵⁴Center for Behavior Genetics of Aging, University of California San Diego, La Jolla, CA, USA. ¹⁵⁵VA San Diego Healthcare System, San Diego, CA, USA. ¹⁵⁶Department of Psychiatry, University of California San Diego, La Jolla, CA, USA. ¹⁵⁷Center of Excellence for Stress and Mental Health, VA San Diego Healthcare System, San Diego, CA, USA. ¹⁵⁸Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, MA, USA. ¹⁵⁹Division of Aging, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. ¹⁶⁰Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy. ¹⁶¹Neurodegenerative Diseases Unit, Fondazione IRCCS Ca' Granda, Ospedale Policlinico, Milan, Italy. ¹⁶²Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy. ¹⁶³Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. ¹⁶⁴Institute of Gerontology and Geriatrics, Department of Medicine and Surgery, University of Perugia, Perugia, Italy. ¹⁶⁵Department of Neurobiology, Care Sciences and Society, Division of Clinical Geriatrics, Karolinska Institutet, Stockholm, Sweden. ¹⁶⁶Interdisciplinary Department of

Medicine, Geriatric Medicine and Memory Unit, University of Bari A. Moro, Bari, Italy. ¹⁶⁷Centre for Memory Disturbances, Laboratory of Clinical Neurochemistry, Section of Neurology, University of Perugia, Perugia, Italy. ¹⁶⁸Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy. ¹⁶⁹Neurology, IRCCS San Gerardo dei Tintori, Monza and University of Milano-Bicocca, Milano, Italy. ¹⁷⁰Department of Clinical and Experimental Sciences, University of Brescia Italy, Brescia, Italy. ¹⁷¹Department of Continuity of Care and Frailty, ASST Spedali Civili Brescia, Brescia, Italy. ¹⁷²Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy. ¹⁷³IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy. ¹⁷⁴Past Director Dementia Unit University of Parma, Parma, Italy. ¹⁷⁵Department of Hematology and Stem Cell Transplant, Vito Fazzi Hospital, Lecce, Italy. ¹⁷⁶Department of Neuroscience Rita Levi Montalcini, University of Torino, Turin, Italy. ¹⁷⁷Department of Neuroscience, Università Cattolica del Sacro Cuore, Rome, Italy. ¹⁷⁸Neurology Unit, IRCCS Fondazione Policlinico Universitario A. Gemelli, Rome, Italy. ¹⁷⁹Laboratory of Neuropsychiatry, IRCCS Santa Lucia Foundation, Rome, Italy. ¹⁸⁰Center for Alzheimer's and Related Dementias, NIH, Bethesda, MD, USA. ¹⁸¹DataTecnica LLC, Washington, DC, USA. ¹⁸²Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, CA, USA. ¹⁸³Pharmaceutical Sciences and Pharmacogenomics Graduate Program, University of California, San Francisco, CA, USA. ¹⁸⁴Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA. ¹⁸⁵Laboratory of Neurogenetics, NIH, Bethesda, MD, USA. ¹⁸⁶Niigata University, Brain Research Institute, Niigata, Japan. ¹⁸⁷Research Center, National Center for Geriatrics and Gerontology, Obu, Japan. ¹⁸⁸UK Dementia Research Institute, Cardiff University, Cardiff, UK. ¹⁸⁹Institute of Neurology, Catholic University of the Sacred Heart, Rome, Italy. ¹⁹⁰Department of Neurology, Amié Hospital, Bangui, Central African Republic. ¹⁹¹Department of Neurology, Brazzaville University Hospital, Brazzaville, Republic of Congo. ¹⁹²Department of Radiology, Indiana University, Indianapolis, IN, USA. ¹⁹³Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. ¹⁹⁴Cluster of Excellence Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany. ¹⁹⁵Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. ¹⁹⁶Department of Epidemiology, ErasmusMC, Rotterdam, the Netherlands. ¹⁹⁷Nuffield Department of Population Health, Oxford University, Oxford, UK. ¹⁹⁸High Institute of Biotechnology, University of Monastir, Monastir, Tunisia. ¹⁹⁹Laboratory of Genetics, Immunology and Human Pathology, Faculty of Science of Tunis, University of Tunis El Manar, Tunis, Tunisia. ²⁰⁰Alzheimer's Centre Reina Sofia-CIEN Foundation-ISCIII, Madrid, Spain. ²⁰¹Centre for Precision Health, Edith Cowan University, Perth, Western Australia, Australia. ²⁰²Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia. ²⁰³Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia. ²⁰⁴Department of Public Health and Caring Sciences/Geriatrics, Uppsala University, Uppsala, Sweden. ²⁰⁵Krembil Brain Institute, University Health Network, Toronto, Ontario, Canada. ²⁰⁶Departments of Medicine and Laboratory Medicine and Pathobiology, Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada. ²⁰⁷Bordeaux Population Health Research Center, INSERM, Bordeaux UMR 1219, Bordeaux, France. ²⁰⁸Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy. ²⁰⁹Centre for Neuropsychiatric Genetics and Genomics, School of Medicine, Cardiff University, Cardiff, UK. ²¹⁰Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Sciences Center, San Antonio, TX, USA. ²¹¹Department of Biomedical Science, Chosun University, Gwangju, Republic of Korea. ²¹²Gwangju Alzheimer's and Related Dementia (GARD) Cohort Research Center, Chosun University, Gwangju, Republic of Korea. ²¹³Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, University of Cologne, Medical Faculty, Cologne, Germany. ²¹⁴German Center for Neurodegenerative Diseases (DZNE Bonn), Bonn, Germany. ²¹⁵Department of Old Age Psychiatry and Cognitive Disorders, University Hospital Bonn, University of Bonn, Bonn, Germany. ²¹⁶Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Disease (CECAD), University of Cologne, Cologne, Germany. ²¹⁷Department of Psychiatry, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA. ²¹⁸Biomedical Genetics/Department of Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA. ³⁴²These authors contributed equally: Aude Nicolas, Richard Sherva, Benjamin Grenier-Boley, Yoonae Kim. ³⁴³These authors jointly supervised this work: Jungsoo Gim, Mark Logue, Jean-Charles Lambert. *A list of authors and their affiliations appears at the end of the paper. ✉e-mail: dr.aude.nicolas.deydier@gmail.com; jean-charles.lambert@pasteur-lille.fr

EADB

Sonia Moreno-Grau^{10,219}, **Najaf Amin**^{196,197}, **Peter A. Holmans**²²⁰, **Luca Klei**^{213,214,221}, **Dag Aarsland**^{222,223}, **Pablo Garcia-Gonzalez**^{10,219}, **Carla Abdelnour**^{10,219}, **Emilio Alarcón-Martín**^{219,224}, **Daniel Alcolea**^{10,225}, **Montserrat Alegret**^{10,219}, **Ignacio Alvarez**^{226,227}, **Nicola J. Armstrong**¹⁵², **Tsolaki Anthoula**^{55,228}, **Ildebrando Appollonio**^{229,230}, **Marina Arcaro**²³¹, **Silvana Archetti**²³², **Alfonso Arias Pastor**^{77,78}, **Lavinia Athanasiu**²³³, **Henri Bailly**¹³², **Nerisa Banaj**²³⁴, **Miquel Baquero**²³⁵, **Ana Belén Pastor**²³⁶, **Sonia Bellini**¹⁶⁰, **Claudine Berr**²³⁷, **Céline Besse**²³⁸, **Valentina Bessi**^{172,239}, **Giuliano Binetti**^{160,240}, **Alessandra Bizarro**²⁴¹, **Rafael Blesa**^{10,225}, **Silvia Boschi**¹⁷⁶, **Paola Bossù**²⁴², **Geir Bråthen**^{243,244}, **Catherine Bresner**²²⁰, **Henry Brodaty**^{152,245}, **Keeley J. Brookes**²⁴⁶, **Dolores Buiza-Rueda**^{10,74}, **Katharina Bürger**^{247,248}, **Vanessa Burholt**^{249,250}, **Miguel Calero**^{10,236,251}, **Geneviève Chene**^{129,130}, **Ángel Carracedo**^{252,253}, **Roberta Cecchetti**²⁵⁴, **Laura Cervera-Carles**^{10,225}, **Camille Charbonnier**²⁵⁵, **Caterina Chillotti**²⁵⁶, **Simona Ciccone**²⁵⁷, **Jordi Clarimon**^{10,225}, **Christopher Clark**²⁵⁸, **Elisa Conti**²²⁹, **Anaïs Corma-Gómez**²⁵⁹, **Guido Maria Giuffrè**²⁶⁰, **Carlo Custodero**²⁶¹, **Delphine Daian**²³⁸, **Efthimios Dardiotis**²⁶², **Peter Paul de Deyn**²⁶³, **Teodoro del Ser**²⁶⁴, **Nicola Denning**²⁶⁵, **Janine Diehl-Schmid**²⁶⁶, **Mónica Díez-Fairen**^{226,227}, **Paolo Dionigi Rossi**²⁵⁷, **Srdjan Djurovic**²³³, **Emmanuelle Duron**¹³², **Sebastiaan Engelborghs**^{267,268,269,270}, **Ana Espinosa**^{10,219}, **Michael Ewers**^{247,248}, **Tagliavini Fabrizio**²⁷¹, **Sune Fallgaard Nielsen**²⁷², **Lucia Farotti**¹⁶⁷, **Chiara Fenoglio**²⁷³, **Marta Fernández-Fuertes**²⁵⁹, **Catarina B. Ferreira**⁸⁴, **Evelyn Ferri**²⁵⁷, **Bertrand Fin**²³⁸, **Peter Fischer**²⁷⁴, **Tormod Fladby**⁹⁸, **Klaus Fließbach**^{214,221}, **Juan Fortea**^{10,225}, **Tatiana M. Foroud**¹¹¹, **Silvia Fostinelli**¹⁶⁰, **Nick C. Fox**²⁷⁵, **Emlio Franco-Macías**²⁷⁶, **Ana Frank-García**^{10,63,277}, **Lutz Froelich**²⁷⁸, **Jose Maria García-Alberca**^{10,79}, **Sebastian Garcia-Madrona**²⁷⁹, **Guillermo Garcia-Ribas**²⁷⁹, **Ina Giegling**²⁸⁰, **Giaccone Giorgio**²⁷¹, **Oliver Goldhardt**²⁶⁶, **Antonio González-Pérez**²⁸¹, **Giulia Grande**¹⁰³, **Emma Green**²⁸², **Tamar Guetta-Baranes**²⁸³, **Annakaisa Haapasalo**²⁸⁴, **Georgios Hadjigeorgiou**²⁸⁵, **Harald Hampel**^{286,287}, **John Hardy**²⁸⁸, **Annette M. Hartmann**²⁸⁰, **Janet Harwood**²²⁰, **Seppo Helisalmi**^{289,290}, **Michael T. Heneka**^{214,221}, **Isabel Hernández**^{10,219}, **Martin J. Herrmann**²⁹¹, **Per Hoffmann**⁵³, **Clive Holmes**²⁹², **Raquel Huerto Vilas**^{77,78}, **Marc Hulsman**^{23,293},

Geert Jan Biessels²⁹⁴, Charlotte Johansson^{295,296}, Lena Kilander¹⁰⁴, Anne Kinhult Ståhlbom^{295,296},
 Miia Kivipelto^{297,298,299,300}, Anne Koivisto^{289,301,302}, Johannes Kornhuber³⁰³, Mary H. Kosmidis³⁰⁴, Carmen Lage^{10,81},
 Erika J. Laukka^{103,305}, Alessandra Lauria²⁴¹, Jenni Lehtisalo^{289,306}, Ondrej Lerch^{87,88}, Alberto Lleó^{10,225},
 Adolfo López-de Munain^{10,307}, Seth Love¹⁹⁵, Malin Löwemark¹⁰⁴, Lauren Luckcuck²²⁰, Juan Macías²⁵⁹,
 Catherine A. MacLeod³⁰⁸, Wolfgang Maier^{214,309}, Francesca Mangialasche²⁹⁷, Marco Spallazzi³¹⁰, Marta Marquie^{10,219},
 Rachel Marshall²²⁰, Angel Martín Montes^{10,63,277}, Carmen Martínez Rodríguez³¹¹, Simon Mead³¹², Miguel Medina^{10,236},
 Alun Meggy²⁶⁵, Silvia Mendoza⁷⁹, Manuel Menéndez-González³¹¹, Merel Mol³¹³, Laura Montreal²¹⁹, Kevin Morgan³¹⁴,
 Markus M. Möthen⁵³, Tiia Ngandu³⁰⁶, Børge G. Nordestgaard^{90,272}, Robert Oloso²³⁸, Adelina Orellana^{10,219},
 Michela Orsini²⁶⁰, Gemma Ortega^{10,219}, Alessandro Padovani³¹⁵, Alba Pérez-Cordón²¹⁹, Pierre Pericard³¹⁶,
 Juan A. Pineda²⁵⁹, Claudia Pisanu¹⁶⁸, Thomas Polak²⁹¹, Danielle Posthuma²⁴, Josef Priller^{33,317}, Olivier Quenez²⁵⁵,
 Inés Quintela²⁵², Alberto Rábano^{10,236,318}, Marcel J. T. Reinders³¹⁹, Peter Riederer³²⁰, Natalia Roberto²¹⁹,
 Arvid Rongve^{321,322}, Irene Rosas Allende^{68,69}, Maitée Rosende-Roca^{10,219}, Jose Luis Royo³²³, Elisa Rubino³²⁴,
 María Eugenia Sáez²⁸¹, Paraskevi Sakka³²⁵, Ingvald Saltvedt^{244,326}, Ángela Sanabria^{10,219}, María Bernal Sánchez-Arjona²⁷⁶,
 Florentino Sanchez-Garcia³²⁷, Pascual Sánchez-Juan^{10,81}, Sigrid B. Sando^{243,244}, Michela Scamosci²⁵⁴, Elio Scarpini^{231,273},
 Martin Scherer³²⁸, Matthias Schmid^{214,329}, Jonathan M. Schott²⁷⁵, Alexey A. Shadrin²³³, Olivia Skrobot¹⁹⁵,
 Alina Solomon^{289,297}, Sandro Sorbi^{172,173}, Oscar Sotolongo-Grau²¹⁹, Annika Spottke^{214,330}, Eystein Stordal³³¹,
 Juan Pablo Tartan²¹⁹, Lluís Tárraga^{10,219}, Niccolò Tesi^{23,293}, Anbupalam Thalamuthu¹⁵², Tegos Thomas⁵⁵,
 Anne Tybjaerg-Hansen^{90,332}, Andre Uitterlinden³³³, Abbe Ullgren²⁹⁵, Ingun Ulstein¹⁰¹, Sergi Valero^{10,219},
 Christine Van Broeckhoven^{334,335,336}, Jasper Van Dongen^{27,334,335}, Rik Vandenbergh^{337,338}, Jean-Sébastien Vidal¹³²,
 Jonathan Vogelgsang^{50,339}, Michael Wagner^{214,221}, Leonie Weinhold³²⁹, Gill Windle³⁰⁸, Bob Woods³⁰⁸,
 Mary Yannakoulia³⁴⁰ & Miren Zulaica^{10,341}

²¹⁹Research Center and Memory Clinic Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain. ²²⁰MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Cardiff, UK. ²²¹Department of Neurodegeneration and Geriatric Psychiatry, University of Bonn, Bonn, Germany. ²²²Centre of Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway. ²²³Institute of Psychiatry, Psychology and Neuroscience, London, UK. ²²⁴Department of Surgery, Biochemistry and Molecular Biology, School of Medicine, University of Málaga, Málaga, Spain. ²²⁵Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. ²²⁶Department of Neurology, Fundació Docència i Recerca Mútua Terrassa and Movement Disorders Unit, University Hospital Mútua Terrassa, Barcelona, Spain. ²²⁷Department of Neurology, Memory Disorders Unit, Hospital Universitari Mútua de Terrassa, Barcelona, Spain. ²²⁸Alzheimer Hellas, Thessaloniki, Greece. ²²⁹School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy. ²³⁰Neurology Unit, San Gerardo Hospital, Monza, Italy. ²³¹Fondazione IRCCS Ca' Granda, Ospedale Policlinico, Milan, Italy. ²³²Department of Laboratory Diagnostics, III Laboratory of Analysis, Brescia Hospital, Brescia, Italy. ²³³NORMENT Centre, University of Oslo, Oslo, Norway. ²³⁴Department of Clinical and Behavioral Neurology, Laboratory of Neuropsychiatry, IRCCS Santa Lucia Foundation, Rome, Italy. ²³⁵Servei de Neurologia, Hospital Universitari i Politècnic La Fe, Valencia, Spain. ²³⁶CIEN Foundation/Queen Sofia Foundation Alzheimer Center, Madrid, Spain. ²³⁷Inserm U1061, Université Montpellier, Neuropsychiatry: Epidemiological and Clinical Research, PSNREC, Montpellier, France. ²³⁸Université Paris-Saclay CEA, Centre National de Recherche en Génomique Humaine, Evry, France. ²³⁹Azienda Ospedaliero-Universitaria Careggi, Florence, Italy. ²⁴⁰MAC Memory Clinic, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy. ²⁴¹Geriatrics Unit Fondazione, Policlinico A. Gemelli IRCCS, Rome, Italy. ²⁴²Department of Clinical and Behavioral Neurology, Experimental Neuro-Psychobiology Laboratory, IRCCS Santa Lucia Foundation, Rome, Italy. ²⁴³Department of Neurology and Clinical Neurophysiology, University Hospital of Trondheim, Trondheim, Norway. ²⁴⁴Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, Trondheim, Norway. ²⁴⁵Dementia Centre for Research Collaboration, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia. ²⁴⁶Biosciences, School of Science and Technology, Nottingham Trent University, Nottingham, UK. ²⁴⁷Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-Universität LMU, Munich, Germany. ²⁴⁸German Center for Neurodegenerative Diseases (DZNE Munich), Munich, Germany. ²⁴⁹Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand. ²⁵⁰Wales Centre for Ageing and Dementia Research, Swansea University, Swansea, Wales, New Zealand. ²⁵¹UFIEC, Instituto de Salud Carlos III, Madrid, Spain. ²⁵²Grupo de Medicina Xenómica, Centro Nacional de Genotipado (CEGEN-PRB3-ISCIII), Universidade de Santiago de Compostela, Santiago de Compostela, Spain. ²⁵³Fundación Pública Galega de Medicina Xenómica—CIBERER-IDIS, University of Santiago de Compostela, Santiago de Compostela, Spain. ²⁵⁴Department of Medicine and Surgery, Institute of Gerontology and Geriatrics, University of Perugia, Perugia, Italy. ²⁵⁵Department of Genetics and CNR-MAJ, UNIROUEN, Inserm U1245 and CHU Rouen, Normandie Université, Rouen, France. ²⁵⁶Unit of Clinical Pharmacology, University Hospital of Cagliari, Cagliari, Italy. ²⁵⁷Geriatric Unit, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Milan, Italy. ²⁵⁸Institute for Regenerative Medicine, University of Zürich, Schlieren, Switzerland. ²⁵⁹Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario de Valme, Seville, Spain. ²⁶⁰Department of Neuroscience, Catholic University of Sacred Heart, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. ²⁶¹University of Bari A. Moro, Bari, Italy. ²⁶²School of Medicine, University of Thessaly, Larissa, Greece. ²⁶³Department of Neurology, University Medical Center Groningen, Groningen, the Netherlands. ²⁶⁴Department of Neurology/CIEN Foundation/Queen Sofia Foundation Alzheimer Center, Groningen, the Netherlands. ²⁶⁵UKDR1@ Cardiff, School of Medicine, Cardiff University, Cardiff, UK. ²⁶⁶Department of Psychiatry and Psychotherapy, School of Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany. ²⁶⁷Center for Neurosciences, Vrije Universiteit Brussel (VUB), Brussels, Belgium. ²⁶⁸Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium. ²⁶⁹Institute Born-Bunge, University of Antwerp, Antwerp, Belgium. ²⁷⁰Department of Neurology, UZ Brussel, Brussels, Belgium. ²⁷¹Fondazione IRCCS, Istituto Neurologico Carlo Besta, Milan, Italy. ²⁷²Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Herlev, Denmark. ²⁷³University of Milan, Milan, Italy. ²⁷⁴Department of Psychiatry, Social Medicine Center East-Donauspital, Vienna, Austria. ²⁷⁵Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UK. ²⁷⁶Unidad de Demencias, Servicio de Neurología y Neurofisiología. Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain. ²⁷⁷Hospital Universitario la Paz, Madrid, Spain. ²⁷⁸Department of Geriatric Psychiatry, Central Institute for Mental Health, Mannheim, University of Heidelberg,

Heidelberg, Germany. ²⁷⁹Hospital Universitario Ramon y Cajal, IRYCIS, Madrid, Spain. ²⁸⁰Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria. ²⁸¹CAEBI, Centro Andaluz de Estudios Bioinformáticos, Sevilla, Spain. ²⁸²Institute of Public Health, University of Cambridge, Cambridge, UK. ²⁸³Human Genetics, School of Life Sciences, Life Sciences Building, University Park, University of Nottingham, Nottingham, UK. ²⁸⁴A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland. ²⁸⁵Department of Neurology, Medical School, University of Cyprus, Nicosia, Cyprus. ²⁸⁶Alzheimer Precision Medicine Initiative (APMI), Sorbonne University, Pitié-Salpêtrière Hospital, Paris, France. ²⁸⁷Eisai Inc., Neurology Business Group, Woodcliff Lake, NJ, USA. ²⁸⁸Department of Molecular Neuroscience, Reta Lila Weston Research Laboratories, UCL Institute of Neurology, London, UK. ²⁸⁹Institute of Clinical Medicine—Neurology, University of Eastern, Kuopio, Finland. ²⁹⁰Institute of Clinical Medicine—Internal Medicine, University of Eastern Finland, Kuopio, Finland. ²⁹¹Department of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital, Würzburg, Germany. ²⁹²Clinical and Experimental Science, Faculty of Medicine, University of Southampton, Southampton, UK. ²⁹³Department of Human Genetics, Section Genomics of Neurodegenerative Diseases and Aging, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. ²⁹⁴Department of Neurology, UMC Utrecht Brain Center, Utrecht, the Netherlands. ²⁹⁵Department NVS, Division of Neurogeriatrics, Karolinska Institutet, Center for Alzheimer Research, Stockholm, Sweden. ²⁹⁶Unit for Hereditary Dementias, Karolinska University Hospital-Solna, Stockholm, Sweden. ²⁹⁷Division of Clinical Geriatrics, Center for Alzheimer Research, Care Sciences and Society (NVS), Karolinska Institutet, Stockholm, Sweden. ²⁹⁸Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland. ²⁹⁹Neuroepidemiology and Ageing Research Unit, School of Public Health, Imperial College London, London, UK. ³⁰⁰Stockholms Sjukhem, Research and Development Unit, Stockholm, Sweden. ³⁰¹Department of Neurology, Kuopio University Hospital, Kuopio, Finland. ³⁰²Departments of Neurosciences and Geriatrics, University of Helsinki, Helsinki University Hospital, Helsinki, Finland. ³⁰³Departments of Psychiatry and Psychotherapy, Universitätsklinikum Erlangen and Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany. ³⁰⁴Laboratory of Cognitive Neuroscience, School of Psychology, Aristotle University of Thessaloniki, Thessaloniki, Greece. ³⁰⁵Stockholm Gerontology Research Center, Stockholm, Sweden. ³⁰⁶Public Health Promotion Unit, Finnish Institute for Health and Welfare, Helsinki, Finland. ³⁰⁷Department of Neurology, Hospital Universitario Donostia, OSAKIDETZA-Servicio Vasco de Salud, San Sebastian, Spain. ³⁰⁸School of Health Sciences, Bangor University, Gwynedd, UK. ³⁰⁹Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany. ³¹⁰Unit of Neurology, University of Parma and AOU, Parma, Italy. ³¹¹Servicio de Neurología Hospital Universitario Central de Asturias- Oviedo and Instituto de Investigación Biosanitaria del Principado de Asturias, Oviedo, Spain. ³¹²MRC Prion Unit at UCL, UCL Institute of Prion Diseases, London, UK. ³¹³Department of Neurology, ErasmusMC, Rotterdam, the Netherlands. ³¹⁴Human Genetics, School of Life Sciences, University of Nottingham, Nottingham, UK. ³¹⁵Department of Clinical and Experimental Sciences, Centre for Neurodegenerative Disorders, University of Brescia, Brescia, Italy. ³¹⁶CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, Université Lille, Lille, France. ³¹⁷Department of Neuropsychiatry and Laboratory of Molecular Psychiatry, Charité, Berlin, Germany. ³¹⁸BT-CIEN, Delft, the Netherlands. ³¹⁹Delft Bioinformatics Laboratory, Delft University of Technology, Delft, the Netherlands. ³²⁰Center of Mental Health, Clinic and Policlinic of Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Würzburg, Würzburg, Germany. ³²¹Department of Research and Innovation, Helse Fonna Hugesund Hospital, Hugesund, Norway. ³²²The University of Bergen, Institute of Clinical Medicine (K1), Bergen, Norway. ³²³Departamento de Especialidades Quirúrgicas, Bioquímicas e Inmunología, School of Medicine, University of Málaga, Málaga, Spain. ³²⁴Department of Neuroscience and Mental Health, AOU Città della Salute e della Scienza di Torino, Turin, Italy. ³²⁵Athens Association of Alzheimer's disease and Related Disorders, Athens, Greece. ³²⁶Department of Geriatrics, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway. ³²⁷Department of Immunology, Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Spain. ³²⁸Department of Primary Medical Care, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany. ³²⁹Institute of Medical Biometry, Informatics and Epidemiology, University Hospital of Bonn, Bonn, Germany. ³³⁰Department of Neurology, University of Bonn, Bonn, Germany. ³³¹Department of Psychiatry, Namsos Hospital, Namsos, Norway. ³³²Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark. ³³³Department of Internal medicine and Biostatistics, ErasmusMC, Rotterdam, the Netherlands. ³³⁴Laboratory of Neurogenetics, Institute Born - Bunge, Antwerp, Belgium. ³³⁵Department of Biomedical Sciences, University of Antwerp, Neurodegenerative Brain Diseases Group, Center for Molecular Neurology, VIB, Antwerp, Belgium. ³³⁶Neurodegenerative Brain Diseases Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium. ³³⁷Department of Neurosciences, Laboratory for Cognitive Neurology, University of Leuven, Leuven, Belgium. ³³⁸Neurology Department, University Hospitals Leuven, Leuven, Belgium. ³³⁹Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, MA, USA. ³⁴⁰Department of Nutrition and Dietetics, Harokopio University, Athens, Greece. ³⁴¹Neurosciences Area, Instituto Biodonostia, San Sebastian, Spain.

Methods

Sample and variant quality controls

Written informed consent was obtained from study participants or, for those with substantial cognitive impairment, a caregiver, legal guardian or other proxy. Study protocols for all cohorts were reviewed and approved by the appropriate institutional review boards (Supplementary Information).

To ensure that the β values were completely independent of the summary statistics, all samples from ADGC, CHARGE and FinnGen GWASs were filtered out. Sample overlap was assessed systematically, and there was no sample overlap between any of the non-US studies analyzed. Overlap between Alzheimer's Disease Sequencing Project ADSP and MVP is likely to be negligible—no more than a few cases. For the biomarker analysis, there is a 460-sample overlap between the American samples used in the biomarker analyses and the ADGC (which is included in the summary statistics we used to generate the β values for the PGS^{ALZ}). However, this overlap is small (less than 2.5%). Furthermore, we analyzed the association of PGS^{ALZ} only with quantitative traits (p-tau, tau and A β 42 CSF concentrations) in these samples, which limited the risk of inflation.

After each sample had met the conventional GWAS gold standard for quality control, it was included in the analyses¹⁶. If a discordance in a variant dose, covariate or *APOE* status (the difference between the imputation and the genotyping results (if available)) was observed, the sample was discarded. After the quality control, each study's demographics were described (Supplementary Table 1)³⁷. Genotyped variants had to meet the gold standard for GWAS variant quality control¹⁶. All studies containing genotyping data were imputed with the TOPMed reference panel^{37,38}. If the variants were imputed, those with an R^2 value below 0.3 were excluded. For whole-genome sequencing data, only variants passing the corresponding quality control were selected (see the Supplementary Information for the ADSP and China samples) (Supplementary Table 2). The global ancestry of each person in the ADSP samples was determined with SNPweights v.2.1 (ref. 39) using a set of ancestry-weighted variants computed on reference populations from the 1000 Genomes Project (as in ref. 40). By applying a global ancestry percentage cutoff of >75%, the samples were assigned to the different ancestry populations. The ancestry of MVP participants was determined using the harmonized ancestry and race/ethnicity (HARE) method⁴¹. HARE is like other genotype-based ancestry calling methods, except that concordance between self-reported ancestry and genetically inferred ancestry is checked. Participants with discrepant ancestry calls are not assigned to a HARE category. Within-group principal components (PCs) for ancestry were computed using FlashPCA2 (ref. 42).

Mega-analysis of European populations

We merged samples from five datasets: EADB-core, GERAD, EADI, Demgene and Bonn. To adjust for population structure, we computed PCs using the following procedure. From the list of 146,705 variants used in the PC analysis of EADB-core⁴², we extracted the TOPMed imputed variants with an imputation quality ≥ 0.9 in each dataset; this resulted in 91,353 variants. Next, we set a genotype to 'missing' if none of the genotype probabilities were greater than 0.8. Finally, all datasets were merged, and variants with a proportion of missing genotypes greater than 0.02 were removed. Ultimately, 90,471 variants were included in the PC analysis (performed with FlashPCA2). The analyses were adjusted for the first 14 PCs, the genotyping chip and the center.

PGS and PRS computations

All codes for PGS and PRS analyses have been made available⁴³. The equation used to calculate the PGSs and the PRSs is as follows:

$$\text{PGS}_{\text{sample}}^{\text{ALZ}} \text{ or } \text{PRS}_{\text{sample}} = \sum_{i=1}^n (\beta_i \times \text{genotype}_{i, \text{sample}})$$

where the $\text{PGS}_{\text{sample}}^{\text{ALZ}}$ PRS_{sample} is the sum per sample of the product of the variant i effect size β_i (extracted from GWAS summary statistics) and the number of risk alleles of this variant i (either as a dosage or as a genotype).

PGS^{ALZ} includes the 83 independent signals associated with AD¹³ and listed in Supplementary Table 1. We also calculated another PGS^{ALZ} combining the same 83 independent signals and the two SNPs encoding the *APOE* $\epsilon 2$ (rs7412) and *APOE* $\epsilon 4$ alleles (rs429358). PGS^{APOE} includes only these two last SNPs. The stage I meta-analysis of EADB studies¹³ (without the United Kingdom (UK) Biobank samples) contained 36,659 clinically diagnosed AD cases, and the stage II meta-analysis (including the ADGC, CHARGE and FinnGen data) contained 25,392 (ref. 13). To ensure independence between the samples and the GWAS summary statistics, the European summary statistics used in the PGS analyses were from stage II. In the PGS^{ALZ}/PRS analyses adjusted for the difference in distribution between populations, the European more powerful summary statistics (that is, the stage I meta-analysis of EADB) were preferred.

The PGS^{ALZ} score was developed to include additional SNPs in the GWAS-defined loci, to capture more genetic information in non-European ancestry populations. First, the 'start and end positions' of each locus (as specified in the GRCh38 assembly) were defined manually by looking at the regional plots and extracting (1) recombination rate peak positions, (2) chromosome start and end positions, (3) specific variant positions or (4) the start/end positions of regions containing no variants. Next, insertions and deletions were excluded. Variants that were not ambiguous (that is, A/T or C/G) and present in the 1000 Genomes Phase 3 data (1000GP3) and had an imputation quality above 0.3 in the EADB-core TOPMed imputations were selected. To extract information on these variants in non-European ancestry populations, we used the summary statistics generated by Lake et al., Shigemizu et al. and Kunkle et al. to represent Latin American, East Asian and African American ancestries, respectively^{25–27}. Since these summary statistics were based on the GRCh37 assembly, we lifted their positions and alleles in the GRCh38 assembly by using the Picard LiftoverVcf tool (v.2.27.5) and restricting the process to variants with a minor allele frequency above 0.01. To remove variants in linkage disequilibrium with the sentinel variant of each locus, we computed the linkage disequilibrium for each sentinel variant versus all the other variants in the locus by using the 1000GP3 data restricted to samples representing European ancestries (the EUR superpopulation), Latin American ancestries (the AMR superpopulation plus the IBS population), Japanese ancestries (the JPT population) and African American ancestries (the AFR superpopulation). Since one of the sentinel variants (chr. 9:104903697:C:G) was not present in the 1000GP3 data, we replaced it with a proxy variant (chr. 9:104903754:G:GC, $R^2 = 1$ in the EUR superpopulation). In each set of summary statistics, we removed variants with $R^2 > 0.1$ in either the European summary statistics or the summary statistics for the corresponding ancestry. Finally, we performed a clumping procedure on the remaining variants in each of the three ancestries by using plink v.1.9, a P value threshold of 1×10^{-3} , an R^2 of 0.05 (as estimated in the corresponding 1000GP3 data samples, as described above) and a distance of 1 Mb. For the PGS^{ALZ+}, this led us to select 30, 13 and 47 variants (in addition to the initial 85 PGS variants) for the Latin American, East Asian and African American ancestries, respectively.

At the time of our analysis, PRS-CSx^{20,44} was one of the best-performing methods for modeling a cross-ancestry PRS^{45,46} without a validation dataset and using GWAS summary statistics. With a Bayesian high-dimensional regression framework model based on continuous shrinkage priors, the variant effect sizes were adaptively re-estimated by coupling cross-ancestry GWAS summary statistics^{13,25–27}, external ancestry-matched allele frequencies and local linkage disequilibrium structure, according to a global shrinkage parameter. This global shrinkage parameter corresponded to the sparseness of the genetic

architecture of AD by avoiding overshrinkage of true signals and by shrinking noisy signals. The sparseness was modeled for the values of $1, 10^{-2}, 10^{-4}, 10^{-5}, 10^{-6}, 10^{-7}$ and 10^{-8} , with the `--meta` option and the Strawderman–Berger prior default parameters ($a = 1$ and $b = 0.5$). The initial 1,297,432 variants present in the 1000 Genomes reference panel were lifted over in GRCh38. Next, new ancestry-specific or joint-ancestry effect size estimates were obtained with PRS-CSx, leading to a maximum number of 1,292,532 variants in the joint-ancestry summary statistics and potentially included in the PRS computations. The PRSs were computed per chromosome with joint-ancestry, European ancestry and ancestry-specific PRS-CSx-effect size estimates, using PLINK (v.2.0.a) software⁴⁷ and its `--score` option. Finally, the PRSs were summed across all chromosomes.

Adjustment for interpopulation differences in the PGS^{ALZ}/PRS distribution

To account for the population structure, PRS_{raw} and PGS^{ALZ}_{raw} were adjusted for interpopulation differences in distribution⁴⁸. The adjustment was performed with a selection of 84,035 independent and well-imputed ($R > 0.8$) variants common to all studies. Starting from this list of variants, FlashPCA2 projected the samples into the 1000GP3 PC-space and calculated the projected PCs. For each study, the raw score was fitted into a linear model in controls, according to the first five projected PCs. This model was used to compute a predicted score in all the samples. The resulting adjusted score was the difference between the raw score and the predicted score.

Statistical analyses

The PGSs and PRSs were standardized to a normal distribution, using the mean and s.d. calculated for the samples as a whole. The associations between AD status and the various scores were tested in logistic regressions named according to the score and the covariates used. Hence, the name ‘ALZinclAPOE’ was attributed if the score included variants in the APOE region (from 43 Mb to 47 Mb). The other covariates included age and sex, as well as the covariates specific to each study (Supplementary Table 2).

- Model PGS^{ALZ}: AD ~ PGS^{ALZ} + COV
- Model PGS^{ALZ}: AD ~ PGS^{ALZ} + COV + the count of APOE ε2 alleles + the count of APOE ε4 alleles (when adjusted for APOE)
- Model PRS: AD ~ PRS + COV
- Model PRS: AD ~ PRS + COV + the count of APOE ε2 alleles + the count of APOE ε4 alleles (when adjusted for APOE)
- Model PRS^{ALZinclAPOE}: AD ~ PRS^{ALZinclAPOE} + COV

To estimate the proportion of phenotypic variance explained by the variance in the score, we computed Nagelkerke’s Pseudo- R^2 _{Full} using the Nagelkerke function implemented in the `rcompanion` package in R^{49,50}. A Pseudo- R^2 _{Null} was also computed for the covariates only. The adjusted Pseudo- R^2 is the difference between Pseudo- R^2 _{Full} and the tied Pseudo- R^2 _{Null}. This adjusted Pseudo- R^2 corresponds to the phenotypic variance explained by the genetic score only. The adjusted Pseudo- R^2 was also transformed into a liability scale for ascertained case–control studies⁵¹, using a prevalence value of 0.15. We consider this value of 0.15 to be consistent for populations with a mean age greater than 75 years. However, this prevalence is different in multiethnic populations of the same mean age. Furthermore, the AD prevalence increases with age, so genetic liability is not homogeneous in all age groups. AD heritability cannot be expressed as a single number because it depends on the ages of the cases and controls⁵².

Quantile and percentile analyses

Depending on the value of the corresponding PGS^{ALZ}, the samples were classified into the reference group or into one of the test groups. In the mega-analysis, the reference group corresponded to the 40–60%

percentile and was tested across other percentiles (0–2%, 2–5%, 5–10%, 10–20%, 20–40%, 60–80%, 80–90%, 95–98% and 98–100%). In the APOE-stratified analysis and in the multiethnic analyses, the reference group was defined as the 40–60% percentile and was tested across the other quintiles (0–20%, 20–40%, 60–80%, 80–100%). The multiethnic analyses were performed on each population and then meta-analyzed per genetic ancestry by using the inverse variance method, as implemented in METAL⁵³. It should be noted that the Indian, North African and sub-Saharan African populations were excluded because of their small sample size.

- Model PGS^{ALZ}: AD ~ Group_{0/1}(PGS^{ALZ}) + COV
- Model PGS^{ALZ}: AD ~ Group_{0/1}(PGS^{ALZ}) + COV + number of APOE ε2 alleles + number of APOE ε4 alleles (when adjusted for APOE)
- Model PGS^{ALZinclAPOE}: AD ~ Group_{0/1}(PGS^{ALZinclAPOE}) + COV

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

The EADB GWAS (without UK biobank) summary statistics used to develop PRS have been deposited with the European Bioinformatics Institute GWAS Catalog under accession no. [GCST90565439](https://www.ebi.ac.uk/ena/record/GCST90565439). Summary statistics from African American multiethnicity population used to develop PRS were accessed through NIAGADS under accession number [NG00100](https://www.niagads.org/datasets/ng000100). Summary statistics from Japan populations were accessed through the National Bioscience Database Center (NBDC) at the Japan Science and Technology Agency (JST) with accession number [hum0237.v1.gwas.v1](https://www.niagads.org/datasets/ng000100). 1000GP3 data is available at http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/data_collections/1000_genomes_project/release/20190312_biallelic_SNV_and_INDEL/. GRCh37 assembly data is available at https://ftp.ncbi.nlm.nih.gov/genomes/all/GCF/000/001/405/GCF_000001405.25_GRCh37.p13/GCF_000001405.25_GRCh37.p13_genomic.fna.gz. GRCh38 assembly data is available at https://ftp.ncbi.nlm.nih.gov/genomes/all/GCF/000/001/405/GCF_000001405.39_GRCh38.p13/GCF_000001405.39_GRCh38.p13_genomic.fna.gz. ADSP data is available at <https://dss.niagads.org/datasets/ng00067/>.

Code availability

All codes developed and shared with collaborators to run PGS and PRS are available via Zenodo at <https://doi.org/10.5281/zenodo.15164089> (ref. 43). Based on IRB and protected status of the Latin American population in dbGaP access process for this data, the summary statistics of the Latin American GWAS cannot be shared. The code to generate it as well as the mandated dbGaP link are respectively available here: https://github.com/NIH-CARD/MA_MA_meta and https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000496.v1.p1. SNPweights v.2.1. is available at <https://hsph.harvard.edu/research/price-lab/software/>. FlashPCA2 is available at <https://github.com/gabraham/flashpca>. Picard LiftoverVcf tool (v.2.27.5) is available at <https://broadinstitute.github.io/picard/>. plink v.1.9 is available at <https://www.cog-genomics.org/plink2/>. PLINK (v.2.0.a) is available at <https://www.cog-genomics.org/plink/2.0/>. `rcompanion` package is available at <https://cran.r-project.org/web/packages/rcompanion/>. METAL v2020–05–05 is available at <https://github.com/statgen/METAL>.

References

- Das, S. et al. Next-generation genotype imputation service and methods. *Nat. Genet.* **48**, 1284–1287 (2016).
- Taliun, D. et al. Sequencing of 53,831 diverse genomes from the NHLBI TOPMed program. *Nature* **590**, 290–299 (2021).

39. Chen, C.-Y. et al. Improved ancestry inference using weights from external reference panels. *Bioinformatics* **29**, 1399–1406 (2013).
40. Le Guen, Y. et al. Multiancestry analysis of the HLA locus in Alzheimer's and Parkinson's diseases uncovers a shared adaptive immune response mediated by HLA-DRB1*04 subtypes. *Proc. Natl Acad. Sci. USA* **120**, e2302720120 (2023).
41. Fang, H. et al. Harmonizing genetic ancestry and self-identified race/ethnicity in genome-wide association studies. *Am. J. Hum. Genet.* **105**, 763–772 (2019).
42. Abraham, G., Qiu, Y. & Inouye, M. FlashPCA2: principal component analysis of Biobank-scale genotype datasets. *Bioinformatics* **33**, 2776–2778 (2017).
43. Nicolas, A. Transferability of European-derived Alzheimer's disease polygenic risk scores across multi-ancestry populations. *Zenodo* <https://doi.org/10.5281/zenodo.15164089> (2025).
44. Ruan, Y. et al. Improving polygenic prediction in ancestrally diverse populations. *Nat. Genet.* **54**, 573–580 (2022).
45. Ma, Y. & Zhou, X. Genetic prediction of complex traits with polygenic scores: a statistical review. *Trends Genet.* **37**, 995–1011 (2021).
46. Kurniansyah, N. et al. Evaluating the use of blood pressure polygenic risk scores across race/ethnic background groups. *Nat. Commun.* **14**, 3202 (2023).
47. Chang, C. C. et al. Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience* **4**, 7 (2015).
48. Hao, L. et al. Development of a clinical polygenic risk score assay and reporting workflow. *Nat. Med.* **28**, 1006–1013 (2022).
49. Lee, S. H., Goddard, M. E., Wray, N. R. & Visscher, P. M. A better coefficient of determination for genetic profile analysis. *Genet. Epidemiol.* **36**, 214–224 (2012).
50. Choi, S. W., Mak, T. S.-H. & O'Reilly, P. F. Tutorial: a guide to performing polygenic risk score analyses. *Nat. Protoc.* **15**, 2759–2772 (2020).
51. Lee, S. H. & Wray, N. R. Novel genetic analysis for case-control genome-wide association studies: quantification of power and genomic prediction accuracy. *PLoS ONE* **8**, e71494 (2013).
52. Baker, E. et al. What does heritability of Alzheimer's disease represent? *PLoS ONE* **18**, e0281440 (2023).
53. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* **26**, 2190–2191 (2010).
- S.v.d.L., C.B., F.K., O.P., A. Schneider, M.D., D.R., N. Scherbaum, J.D., S.R.-H., L.H., L.M.-P., E.D., T.G., J. Wiltfang, S.H.-H., S. Moebus, T.T., N. Scarneas, O.D.-I., F.M., J.P.-T., M.J.B., P.P., R.S.-V., V.Á., M.B., P.G.-G., R. Puerta, P. Mir, L.M.R., G.P.-R., J.M.G.-A., J.L.R., E.R.-R., H. Soininen, T.K., A.d.M., S. Mehrabian, J. Hort, M.V., K.L.R., J.Q.T., Y.A.L.P., H.H. J.C.v.S., H. Seelaar, J.A.H.R.C., W.J.S., I. Ramakers, F.V., A.v.d.L. P. Scheltens, S.B., V.F., G.S., C.G., G.P., V.G., G.N., C. Dufouil, F.P., O.H., S.D., A.B., J.-F. Deleuze, E.G., J.P., P. Sachdev, K.A.M., D.G., B. Arosio, P. Mecocci, V.S., L.P., A. Squassina, L.T., B. Borroni, B.N., P.C., D.S., I. Rainero, A. Daniele, J. Williams, C. Masullo, P.A., F.J., P.K., C.V.D., R.F.-S., M.T., P.S.-J., K.S., M.I., G.R., M.H., R. Sims, W.v.d.F., O.A.A., A. Ruiz, A. Ramirez and J.-C.L. contributed to EADB sample collection, T.P. and S.M.L. provided the Australian sample. R. Sherva, R.L.H., V.M., M.P., R.Z., J.M.G., C.L.L. and M.L. contributed the MVP sample. M. Goss, C.L.B., B.F., Q.Y., A.J.G., T.F., J. Haines, L.F., A. DeStefano, E.W., R.M., M. P.-V., B.K., A. Goate, G.D.S., B.V., L.-S.W., Y.Y.L., C.L.D., A. Saykin, H.L.L., J.S.Y., M.A.N., S.S. and C. Cruchaga provided US populations. M. Guerchet, P.-M.P., P. Mbelesso, B. Bandzouzi, N.B.S., L. Cherni and J.-F. Dartigues contributed the African sample. Y.K., M.K., X.Z., H.C., N.Y.I., A.K.Y.F., F.C.F.I., A.M., N.H., K.O., S.N., J.G., V.E.-P., K.H.L. and T.I. contributed the East Asia sample. M.C.D., C.E.A.-B., M.A.C.B., N.O., T.J.-C., C. Muchnik, C. Cuesta, L. Campanelli, P. Solis, D.G.P., S.K., L.I.B., J.O.-R., A.G.C.M., M.F.M., R. Pardo, G.A., L.A.d.M., M.A.R.S., B.d.M.V., M.T.G.C., T.J.-C., B. Angel, S.G., M.V.C., R.A., P.O., A. Slachevsky, C.G.-B., C.A., P.F., E.N.d.M., L.M., H.A., A. Ruiz and A. Ramirez contributed the South America sample. The core writing group were A.N., B.G.-B. and J.-C.L.

Competing interests

S.v.d.L. is a recipient of funding from ABOARD, which is a public-private partnership financed by ZonMW (no. 73305095007) and Health-Holland. Topsector Life Sciences & Health (PPP-allowance; no. LSHM20106). C.C. has received research support from GSK and EISAI. The study's funders had no role in the collection, analysis or interpretation of data; in the writing of the report or in the decision to submit the paper for publication. C.C. is an advisory board member for Vivid Genomics and Circular Genomics and owns stock. L.M.-P. received personal fees from Biogen for consulting activities unrelated to the submitted work. T.G. received consulting fees from AbbVie, Alector, Anavex, Biogen, Cogthera, Eli Lilly, Functional Neuromodulation, Grifols, Iqvia, Janssen, Noselab, Novo Nordisk, NuiCare, Orphanzyme, Roche Diagnostics, Roche Pharma, UCB and Vivoryon; lecture fees from Biogen, Eisai, Grifols, Medical Tribune, Novo Nordisk, Roche Pharma, Schwabe and Synlab; and has received grants to his institution from Biogen, Eisai and Roche Diagnostics. O.A.A. is a consultant to Cortechs and Precision Health AS, and has received speaker's honoraria from Lundbeck, Sunovion, Otsuka and Janssen. The other authors declare no competing interests.

Additional information

Extended data is available for this paper at <https://doi.org/10.1038/s41588-025-02227-w>.

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41588-025-02227-w>.

Correspondence and requests for materials should be addressed to Aude Nicolas or Jean-Charles Lambert.

Peer review information *Nature Genetics* thanks the anonymous reviewers for their contribution to the peer review of this work. Peer reviewer reports are available.


Reprints and permissions information is available at www.nature.com/reprints.

Acknowledgements

We thank all the study participants, researchers and staff for contributing to, or collecting, the data. We also thank the staff at the University of Lille's high-performance computing service. This work was funded by a grant (European Alzheimer&Dementia DNA BioBank, EADB) from the EU Joint Programme—Neurodegenerative Disease Research (JPND) and La Fondation Recherche Alzheimer. This work was supported by Mécénat Mutuelles AXA. A.N. was funded by La Fondation pour la Recherche Médicale (EQU202003010147) and La Fondation Recherche Alzheimer. UMR1167 is also funded by the INSERM, Institut Pasteur de Lille, Lille Métropole Communauté Urbaine and the French government's LABEX DISTALZ program (development of innovative strategies for a transdisciplinary approach to Alzheimer's disease). Full consortium acknowledgements and funding are given in the Supplementary Note. We thank D. Fraser (Biotech Communication SARL, Ploudalmézeau, France) for editorial assistance.

Author contributions

A.N. and J.-C.L. coordinated the project. A.N., Y.L.G., J.G., M.D.G., S.v.d.L., E.N.D.M., J.-F.D., H.A., V.E.-P., A. Ruiz, K.H.L., T.I., A. Ramirez, M.L. and J.-C.L. coordinated data collection. A.N., R. Sherva, B.G.-B., Y.K., M.K., J.T., I.D.R., C.D., X.Z., Y.L.G., C.E.A.-B., M.A.C.B., M. Guerchet, S.v.d.L., M. Goss, A.C., C.B. and F.K. analyzed the data. I.d.R., A.C.,




Extended Data Fig. 1 | Association of PGS^{ALZ} with the risk of developing AD (a) in 17 European countries and (b) in Men and Women. Ncases, number of cases; Ncontrols, number of controls; OR, Odds ratio per Standard deviation were

calculated using logistic regressions adjusted for age, gender and PCs according to the population studied (Supplementary Table 2). The lines in the Forest plots indicate the 95% confidence interval for the ORs.

a


PGS^{ALZ}
 $I^2 = 62.4$, HetP = $1.42e-03$

Country	Ncases	Beta	95% CI	P-value
Finland	1,118	-0.47	[-0.95;0.02]	5.99e-02
Norway	1,327	-0.29	[-0.77;0.19]	2.39e-01
Sweden	1,466	-1.45	[-2.01;-0.88]	5.30e-07
Denmark	398	-0.39	[-1.16;0.38]	3.19e-01
United Kingdom	4,622	-0.57	[-0.85;-0.29]	7.29e-05
The Netherlands	2,428	-0.05	[-0.47;0.36]	8.00e-01
Belgium	1,211	-0.63	[-0.93;-0.32]	5.95e-05
Germany	2,190	-0.92	[-1.30;-0.54]	2.79e-06
Austria/Switzerland	175	-0.46	[-1.35;0.42]	3.04e-01
Bulgaria/Greece	735	-0.13	[-0.74;0.48]	6.67e-01
Italy	2,973	-0.34	[-0.66;-0.02]	3.76e-02
France	3,789	-1.04	[-1.38;-0.69]	3.18e-09
Spain	3,103	-0.45	[-0.76;-0.14]	4.85e-03
Meta-analysis	25,535	-0.56	[-0.75;-0.37]	6.87e-09

**b**


PGS^{ALZ} (Adjusted on APOE)
 $I^2 = 60.9$, HetP = $2.17e-03$

Country	Ncases	Beta	95% CI	P-value
Finland	1,118	-0.33	[-0.81;0.15]	1.72e-01
Norway	1,327	-0.28	[-0.75;0.20]	2.57e-01
Sweden	1,466	-1.35	[-1.89;-0.82]	8.54e-07
Denmark	398	-0.40	[-1.16;0.35]	2.93e-01
United Kingdom	4,622	-0.53	[-0.81;-0.25]	2.01e-04
The Netherlands	2,428	-0.05	[-0.47;0.36]	8.01e-01
Belgium	1,211	-0.61	[-0.91;-0.31]	6.06e-05
Germany	2,190	-0.88	[-1.25;-0.50]	4.93e-06
Austria/Switzerland	175	-0.49	[-1.37;0.40]	2.81e-01
Bulgaria/Greece	735	-0.13	[-0.75;0.48]	6.66e-01
Italy	2,973	-0.32	[-0.64;-0.01]	4.62e-02
France	3,789	-1.01	[-1.35;-0.67]	5.83e-09
Spain	3,103	-0.42	[-0.73;-0.11]	7.28e-03
Meta-analysis	25,535	-0.54	[-0.72;-0.35]	1.27e-08



Extended Data Fig. 2 | Associations between (a) PGS^{ALZ} or (b) PGS^{ALZ} adjusted for APOE and age at onset of AD in European countries. N_{cases}, the number of cases. Since HetP < 0.05, the random effect is shown for the meta-analysis results. β s were calculated using a general linear model adjusted for APOE, gender and PCs according to the population studied (Supplementary Table 2).

a




b

Country	Cases			Controls			OR ϵ_4
	ϵ_4	ϵ_3	ϵ_2	ϵ_4	ϵ_3	ϵ_2	
Finland	0.42	0.56	0.02	0.16	0.79	0.05	3.85 [3.33-4.46]
Norway	0.43	0.54	0.03	0.17	0.76	0.08	4.23 [3.62-4.95]
Sweden	0.41	0.57	0.03	0.16	0.77	0.08	3.90 [3.47-4.39]
Denmark	0.34	0.60	0.07	0.15	0.76	0.09	3.51 [2.71-4.53]
United Kingdom	0.33	0.63	0.04	0.13	0.79	0.08	3.39 [3.14-3.67]
The Netherlands	0.42	0.55	0.03	0.19	0.73	0.07	2.67 [2.38-2.98]
Belgium	0.31	0.64	0.05	0.13	0.79	0.08	3.50 [2.92-4.20]
Germany	0.33	0.63	0.05	0.12	0.79	0.09	3.67 [3.28-4.11]
Austria/Switzerland	0.19	0.74	0.07	0.10	0.82	0.08	2.11 [1.43-3.10]
Czech Republic	0.32	0.66	0.02	0.11	0.82	0.07	4.94 [2.22-10.99]
Bulgaria/Greece	0.23	0.74	0.03	0.09	0.85	0.06	2.17 [1.63-2.89]
France	0.30	0.66	0.04	0.10	0.82	0.07	3.65 [3.37-3.94]
Italy	0.25	0.73	0.03	0.09	0.86	0.05	3.69 [3.13-4.36]
Spain	0.27	0.70	0.03	0.10	0.85	0.06	3.73 [3.21-4.33]
Portugal	0.30	0.66	0.04	0.18	0.77	0.05	2.20 [1.19-4.05]

Country	Cases			Controls			OR ϵ_4
	ϵ_4	ϵ_3	ϵ_2	ϵ_4	ϵ_3	ϵ_2	
European American	0.26	0.68	0.06	0.12	0.80	0.08	2.96 [2.78-3.15]
African American	0.36	0.57	0.07	0.20	0.70	0.11	2.59 [2.35-2.84]
US LA Ancestry	0.23	0.73	0.04	0.10	0.85	0.05	2.25 [2.02-2.52]
Maghreb	0.27	0.72	0.02	0.10	0.87	0.03	5.46 [2.50-11.94]
Sub-Saharan Africa	0.28	0.62	0.11	0.23	0.65	0.12	1.36 [0.91-2.03]
Colombia	0.31	0.66	0.03	0.14	0.81	0.05	2.85 [1.97-4.13]
Brazil	0.28	0.68	0.03	0.12	0.81	0.07	3.73 [2.44-5.69]
Argentina	0.27	0.70	0.03	0.11	0.84	0.05	2.40 [1.73-3.33]
Chile	0.29	0.70	0.01	0.10	0.86	0.04	3.64 [2.26-5.86]
China	0.21	0.72	0.07	0.08	0.83	0.09	3.26 [2.49-4.26]
Japan	0.31	0.67	0.02	0.09	0.87	0.05	4.83 [4.24-5.49]
South Korea	0.26	0.70	0.04	0.08	0.86	0.06	3.64 [3.02-4.38]
India	0.17	0.79	0.04	0.11	0.84	0.05	1.61 [1.08-2.39]
Australia	0.40	0.57	0.03	0.14	0.77	0.09	4.16 [3.43-5.04]

Extended Data Fig. 3 | Distribution and association of *APOE* $\epsilon_2/\epsilon_3/\epsilon_4$ alleles with AD risk worldwide. (a) World map showing the populations analyzed. A color gradient indicates the strength of the association between *APOE* $\epsilon_2/\epsilon_3/\epsilon_4$ alleles and the risk of developing AD in different countries (b) frequencies of *APOE* $\epsilon_2/\epsilon_3/\epsilon_4$ alleles in case and controls as well association of *APOE* ϵ_4 alleles with the

risk of developing AD in different countries. OR, Odds ratio were calculated using logistic regressions adjusted for age, gender and PCs according to the population studied (Supplementary Table 2). Sample sizes are reported in Supplementary Table 2. The map was generated using ggplot2 and royalty-free data from rnaturalearth (<https://www.naturalearthdata.com/about/terms-of-use/>).



Extended Data Fig. 4 | See next page for caption.

Extended Data Fig. 4 | Association between (a) PGS^{ALZ} or (b) PGS^{ALZ} (adjusted for *APOE*) and age at onset of AD in multi-ancestry populations. N_{cases} , number of cases. The African-American-ancestry meta-analysis (more than 75% of the population with African-American ancestry) included the MVP and ADSP datasets. The East Asia meta-analysis included datasets from China, Korea, and

Japan. The Latin American (LA) ancestry (self-reporting) meta-analysis included the MMVP and ADSP datasets. The South America meta-analysis included the datasets from Argentina, Brazil, Chile, and Colombia. * not used in the meta-analysis. β s were calculated using a general linear model adjusted for gender and PCs according to the population studied (Supplementary Table 2).

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- ☐ ☒ The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- ☐ ☒ A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- ☐ ☒ The statistical test(s) used AND whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- ☐ ☒ A description of all covariates tested
- ☐ ☒ A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- ☐ ☒ A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- ☐ ☒ For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
Give P values as exact values whenever suitable.
- ☒ ☐ For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- ☒ ☐ For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- ☐ ☒ Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection	All codes developed and shared with collaborators to run PGS and PRS are available at https://doi.org/10.5281/zenodo.15164089 Based on IRB and protected status of the Latin-American population in dbGaP access process for this data, the summary statistics of the Latin-American GWAS cannot be shared. The code to generate it as well as the mandated dbGaP link are respectively available here: https://github.com/NIH-CARD/MA_MA_meta and https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000496.v1.p1
Data analysis	SNPweights v.2.1., https://hsph.harvard.edu/research/price-lab/software/ FlashPCA2, https://github.com/gabraham/flashpca Picard LiftoverVcf tool (v2.27.5): https://broadinstitute.github.io/picard/ plink v1.9: https://www.cog-genomics.org/plink2/ PLINK (v.2.0.a): https://www.cog-genomics.org/plink/2.0/ rcompanion package: https://cran.r-project.org/web/packages/rcompanion/ METAL v2020-05-05: https://github.com/statgen/METAL

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

The EADB GWAS (without UK biobank) summary statistics used to develop PRS have been deposited to the European Bioinformatics Institute GWAS Catalog (<https://www.ebi.ac.uk/gwas/>) under accession no. GCST90565439.
Summary statistics from African-American multi-ancestry population used to develop PRS were accessed through NIAGADS (<https://www.niagads.org/>) under accession number NG00100.
Summary statistics from Japan populations were accessed through the National Bioscience Database Center (NBDC) at the Japan Science and Technology Agency (JST) at <https://humandbs.biosciencedbc.jp/en/> through accession number hum0237.v1.gwas.v1.
1000GP3: http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/data_collections/1000_genomes_project/release/20190312_biallelic_SNV_and_INDEL/
GRCh37 assembly:
https://ftp.ncbi.nlm.nih.gov/genomes/all/GCF/000/001/405/GCF_000001405.25_GRCh37.p13/GCF_000001405.25_GRCh37.p13_genomic.fna.gz
GRCh38 assembly:
https://ftp.ncbi.nlm.nih.gov/genomes/all/GCF/000/001/405/GCF_000001405.39_GRCh38.p13/GCF_000001405.39_GRCh38.p13_genomic.fna.gz
ADSP: <https://dss.niagads.org/datasets/ng00067/>

Research involving human participants, their data, or biological material

Policy information about studies with [human participants or human data](#). See also policy information about [sex, gender \(identity/presentation\), and sexual orientation](#) and [race, ethnicity and racism](#).

Reporting on sex and gender	All analyses were systematically adjusted for sex
Reporting on race, ethnicity, or other socially relevant groupings	multi-ancestry populations were defined according to genetic structure at the exception of latino-American populations, defined on self-declaration.
Population characteristics	We used multiple independent sets of participants in this study. We adjusted the analysis for principal components. Sample sizes, age and gender characteristics for our sample can be found per cohort and overall in Supplementary Tables 1 and Supplementary Information.
Recruitment	Participants from case-control studies were primarily recruited from clinics, nursing homes, disease registries, and hospitals, with controls being drawn from various ongoing studies and screened to exclude dementia/cognitive decline.
Ethics oversight	Written informed consent was obtained from study participants or, for those with substantial cognitive impairment, from a caregiver, legal guardian, or other proxy, and the study protocols for all populations were reviewed and approved by the appropriate Institutional review boards (IRB's). More details can be found per cohort in Supplementary Information.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences ☐ Behavioural & social sciences ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	Raw data and summary statistics were collected by the EADB consortia and summary statistics were recruited by external sources used for meta-analysis. Sample size was not pre-determined and was chosen based on all known available cohorts with relevant data collected to date, after quality control steps were performed in each cohort (described in detail in Supplementary Information).
Data exclusions	We excluded samples and variants based on standard quality control procedures for GWAS. Details of our quality control procedures are provided in the methods and supplementary information section of the manuscript.
Replication	PGS/PRS analyses were performed in several independent populations when possible
Randomization	The studies used in this work are observational case-control studies, hence there is no equivalent process of randomization.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involved in the study
☒	☐ Antibodies
☒	☐ Eukaryotic cell lines
☒	☐ Palaeontology and archaeology
☒	☐ Animals and other organisms
☒	☐ Clinical data
☒	☐ Dual use research of concern
☒	☐ Plants

Methods

n/a	Involved in the study
☒	☐ ChIP-seq
☒	☐ Flow cytometry
☒	☐ MRI-based neuroimaging

Plants

Seed stocks

Report on the source of all seed stocks or other plant material used. If applicable, state the seed stock centre and catalogue number. If plant specimens were collected from the field, describe the collection location, date and sampling procedures.

Novel plant genotypes

Describe the methods by which all novel plant genotypes were produced. This includes those generated by transgenic approaches, gene editing, chemical/radiation-based mutagenesis and hybridization. For transgenic lines, describe the transformation method, the number of independent lines analyzed and the generation upon which experiments were performed. For gene-edited lines, describe the editor used, the endogenous sequence targeted for editing, the targeting guide RNA sequence (if applicable) and how the editor was applied.

Authentication

Describe any authentication procedures for each seed stock used or novel genotype generated. Describe any experiments used to assess the effect of a mutation and, where applicable, how potential secondary effects (e.g. second site T-DNA insertions, mosaicism, off-target gene editing) were examined.